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Abstract 
 
- The first chapter of this thesis work describes an efficient and ecofriendly synthetic 
methodology of the known 1,3’-diindolylalkanes, which were recently brought to the 
forefront for their anti-carcinogenic properties.  
With a similar procedure, novel indole-1-carbinols and 1,3’-diindolylalkanes were 
synthesized and then subjected to preliminary cytotoxic evaluation on 
hepatocarcinoma cells, showing to be great potential anticancer drugs. 
 
- The second chapter explores possible solutions to the unresolved issue presented by 
the oxidation of a dihydro precursor of the potent telomerase inhibitor, telomestatin. 
The assembly of key polyoxazole building blocks for that natural product is 
discussed. 
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CHAPTER 1: 
NOVEL INDOLE-1-CARBINOLS AND 1,3’-DIINDOLYLALKANES: 
SYNTHESIS AND PRELIMINARY EVALUATION OF THEIR 
CYTOTOXICITY IN HEPATOCARCINOMA CELLS.  
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1. INTRODUCTION 
The development of drug-resistance is still one of the major obstacles for the 
successful treatment of cancer.
 
Thus, although targeted therapy, as the use of specific 
monoclonal antibodies
1
 or immunotoxins,
2
 is promising results in the cure of specific cancers, 
the reduction of efficiency of traditional chemotherapeutic agents poses a serious problem, 
especially at more advanced stages of cancer (metastatic patients).
3
 In many cases, resistance 
to chemotherapy already exists before drug treatment starts, leading the anticancer therapy to 
be ineffective from the very first dose (intrinsic resistance);
 
however, it is more frequently 
observed that cancers which initially respond well to conventional drugs, eventually become 
refractory to the same drug, enabling the treatment to fail. This type of drug-resistance which 
develops on sustained exposure to drugs has been termed acquired resistance.
4
  
Although, during the past 40 years, researchers have been proposing several 
mechanisms in order to rationalize this phenomenon, a clear explanation is not available yet.
3 
Some of these mechanisms, such as loss of a specific drug receptor or transporter, drug 
metabolism or mutation of the drug target, result in resistance to only a small number of 
related drugs.
5
 In these cases, use of multiple drugs with different mechanisms of entry into 
cells and different cellular targets allows for effective chemotherapy and high cure rates. To 
complicate matters, cancer cells can also express mechanisms which confer simultaneous 
resistance to many structurally and functionally different unrelated drugs. This daunting task, 
known as multidrug resistance,
6
 often derives from changes able to reduce the accumulation 
of a drug inside the cells, by limiting uptake, enhancing efflux or affecting membrane lipids 
(Figure 1).
7
 As a consequence of this altered equilibrium, cell apoptosis, which is usually 
activated by anticancer drugs,
8
 results to be arrested as well as the general mechanisms to 
detoxify drugs and to repair damaged DNA. Adding alterations in the cell cycle, it is not 
surprising that cancer cells become relatively resistant to the cytotoxic effects of drugs.
 9 
 2 
 
 
                                               Figure 1. Mechanisms of multidrug resistance. 
In the presence of multidrug resistance, the use of combinational anti-cancer therapy is 
clearly not applicable because the increased drug toxicity would be lethal even for normal 
cells.
 
 The problem is unfortunately still unresolved and awaiting a good solution. 
A sigh of relief in this area is represented by the recent discovery that some natural 
compounds, especially indole derivatives such as indole-3-carbinol (1) and 3,3’-
diindolylmethane (DIM, 2a) act in a pleiotropic way without causing unwanted toxicity in 
normal cells (Figure 2).
4
 Consequently, the association of the latter with conventional 
chemotherapeutic agents, could be useful for the treatment of human malignancies leading to 
diminished toxicity and higher efficacy.
10
 
 
 
1.1 Indole derivatives as co-anticancer drugs 
Indoles are largely present in the vegetable kingdom but particularly associated with 
cruciferous vegetables. Recent epidemiological studies have suggested a directly proportional 
connection between the dietary intake of cruciferous vegetables and the incidence of cancer, 
meaning that populations which consume a higher amount of these vegetables have a lower 
 3 
 
incidence of cancer (or improved biochemical parameters) compared to controls.
11
 It was also 
found that the agents responsible for this preventing anticancer effects are some indole 
derivatives, in particular 1 and 2a.
4
 As mentioned earlier, further studies have proved that 1 
and 2a act in a very unusual way, targeting a plethora of molecular mechanisms with no 
toxicity for norml cells: consequently, these molecules can be considered ideal co-drugs in 
cancer therapy. 
 
1.1.1 Indole-3-carbinol  
Indole-3-carbinol is an indole compound mainly present in the genus Brassica of 
cruciferous family, which includes broccoli, Brussels sprouts, cabbages, cauliflowers, 
mustard and collard greens. Brassica vegetables have been cultivated since antiquity both for 
their pungent taste and their medical value; interestingly, the first to record the word 
“Brassica” in reference to these plants was the roman statesman Cato Major, who wrote: “if a 
cancerous ulcer appears upon the breasts, apply a crushed cabbage leaf and it will make it 
well” (treatise on medicine).12 Thus, crushing cruciferous vegetables liberates the sequestered 
plant enzyme myrosinase, which is responsible for the hydrolysis of glucobrassicin (3), a 
glucosinolate predominant in this type of vegetables. Such hydrolysis generates the instable 
isothiocyanate 4 which upon spontaneous rearrangement finally releases the active 1 (Scheme 
1).
13
  
 
 4 
 
The stability of glucosinolates is strongly influenced by the presence of external factors, 
consequently the amount of 1 formed from glucobrassicin in foods is variable, depending on 
the processing and preparation of those foods.
14 
Recent biological studies showed that 1 is able to suppress proliferation and induce 
apoptosis of various cancer cells, including breast, ovarian, lung, cervical, colon, prostate and 
liver.
15
 The ability of 1 to be efficient against  a variety of cancer cells with different genetic 
and cellular abnormalities is associated with its peculiar mechanism of action; thus, in stark 
contrast to the traditional chemotherapeutic agents which have a single specific target, 1 act 
in a pleiotropic way, meaning that it can affect a broad spectrum of signaling pathways 
governing apoptosis, cell-cycle progression, hormonal homeostasis, DNA repair, 
angiogenesis and multiple-drug resistance.
4 
Among the various mechanisms, it is worth of mention that 1 is able, via phosphorylation, to 
selectively inhibit the activation of the protein kinase Akt (also known as protein kinase B), a 
serine-protein kinase which plays a crucial role in the cycle cell, promoting cell growth and 
motility, glucose metabolism and angiogenesis.
16
 While in normal cells Akt is regularly 
expressed, numerous evidences suggest that this protein is hyperactivated in cancer cells; 
clearly any agent  as 1 capable of inhibiting the protein Akt would ultimately cause cancer 
cell apoptosis.
17
 
An equally intriguing property of 1 is its ability to sensitize cancer cells to standard 
chemotherapeutic agents.
4
 Chemo-sensitization is the process by which a drug modulates 
cellular signaling pathways overcoming the chemo-resistance of established 
chemotherapeutic drugs.
18
 In this contest, 1 has been reported to sensitize multidrug resistant 
tumors to chemotherapeutic drugs without any associated toxicity.
19
 
Despite the great anticancer activity in vitro, the clinical development of 1 has been 
hampered by its poor metabolic profile. Indeed, 1 suffers from acidic instability and/or 
 5 
 
unpredictable pharmacokinetic properties in vivo, which render therapeutic concentrations 
difficult to achieve in the body.
20
 The intrinsic instability of 1 in acidic conditions is certainly 
correlated to its chemical structure: thus, the vinyl hemiaminal moiety of the indole ring 
renders the molecule highly susceptible to acid-catalyzed dehydration generating the 
azafulvene salt 5a which by condensation with one or more units of 1 leads to a complex 
series (ca. twenty) of oligomers.
21 
Among the latter, only four have anticancer activity: the 
linear dimer 2, the linear trimer 6, the cyclic trimer 7 and the cyclic tetramer 8 (Scheme 2).
22
 
The most predominant active oligomer, resulted to be compound 2 which accounts for about 
10-20% of the breakdown products of 1; as 2 induces apoptosis and cell-cycle arrest in cancer 
cells through mechanisms analogous to those of 1, the in vivo anticancer effect of the latter, 
might be at least in part, be attributable to 2.
22
 
 
 
 
The acid lability of 1 could be circumvented by protecting the N atom in order to hinder the 
typical dehydration: it is not a coincidence that many recent investigations have addressed to 
develop derivatives of 1 with improved stability and possibly more potent.
23
 This effort has 
 6 
 
so far culminated in OSU-A9 (cf. 9, Figure 3), an indole-3-carbinol derivative obtained 
through N-protection with a p-chloro-m-nitrobenzenesulfonyl group.
24 
Such modification not 
only improved the acid stability but also resulted in a 100-fold increase of the apoptosis-
inducing potency compared to 1.
24
 
 
 
Equally important, 9 retains the pleiotropic mechanism of 1 in mediating cell-cycle arrest and 
apoptosis induction in cancer cells; moreover, 9 has been shown to suppress prostate tumor 
growth in vivo without causing toxicity, underlying its potential clinical use in cancer 
prevention and/or therapy.
24
 
 
1.1.2 DIM & derivatives 
Compounds of the type 2 (Figure 4), which contain two indole units separated by one 
carbon atom linked to C-3 and C-3' (the so called 3,3’-diindolylalkanes), constitute a 
relatively new and very important class of compounds. Thus, the first isolation of a molecule 
of this sort  
 
sort goes back to 1977 when the hallucinogenic 10 (Figure 5) was isolated by Porter et al. 
from the fungus Balansia epichloë.
25
 Since then, a large number of other diindolylakanes 
 7 
 
have been isolated from terrestrial and marine natural sources, such as parasitic bacteria, 
tunicates, and sponges. 
 
Some of these possess significant biological activities as Vibrindole A (11) and Streptindole 
(12) shown in Figure 6. Compound 11, isolated from the marine bacterium Vibrio 
parahaemolyticus exihibited antibacterial activity against Staphylococcus aureus, 
Staphylococcus albus, and Bacilus subtilis,
26 
while compound 12, isolated from the intestinal 
bacterium Streptococcus faecium IB 37 demonstrated DNA-damaging activity and 
genotoxicity.
27
 
 
In the past decade, the discovery of anti-carcinogenic properties of some diindolylakanes 
have brought to the forefront the importance of these compounds.
28
 
Among them, a particular mention deserves dimer 2a, which it will be recalled to be the 
major metabolite of 1. Compound 2a showed the interesting property of efficiently 
promoting, both in women and men, the metabolism of estradiol,
12 
the principal estrogen 
secreted by ovary.
 
It is now certain that estradiol has an ambivalent nature as it can either sustain health or 
promote cancer when in excess;
29 
in this contest, 2a was found to positively modulate the 
 8 
 
activity of cellular enzymes responsible for estrogen metabolism at a dose of 5.0 mg/Kg per 2 
days,
28a
 so restoring a safer balance.
 
Even more potent anti-estrogenic activity was showed by some dihaloDIMs reported in 2000 
by Safe (Figure 7);
28a
 thus, a dose of only 1.0 mg/Kg per 2 days resulted enough to induce the 
same inhibition level of 2a. 
 
 
 
Because of the anti-estrogenic activity, it is not surprising that 2a is especially active in 
hormonal dependent cancer as breast and prostate cancer.
30 
In addition it should not be overlooked that 2a presents a multiple mechanism of action as 
well as its precursor; as a consequence it is efficient also on non-hormonal dependent cancer 
cells.
28a 
Again, 2a shares the same ability of 1 of sensitizing cancer cells towards the standard 
anticancer drugs. To explain, targeting the oncogenic transcription factor FoxM1, 2a 
enhances sensitivity of breast cancer cells to chemotherapeutic agents such as taxotere.
31
 
Precisely, a combination treatment with 2a and taxotere resulted in a significantly greater 
inhibition of cell growth and induced enhanced apoptosis compared with either agent alone. 
These results were further supported by in vivo studies, which showed that DIM sensitized 
the breast tumors to taxotere, with a greater overall antitumor activity. 
 
 
 
 
 9 
 
2. SYNTHETIC BACKGROUND 
Taking in account the recent anticancer properties of 2a, both in vitro and in vivo, it is 
not surprising that in the last ten years many research groups have addressed their efforts to 
synthesize, efficiently and mildly, compound 2a and its derivatives. 
Initial objective of our research was, indeed, the development of an alternative methodology 
that could circumvent the difficulties posed by the traditional synthetic methods (cf. 
paragraph 2.1 for details) for DIMs. In parallel and more interestingly, we also developed a 
similar procedure for the synthesis of novel indole-N-carbinols (cf. 16, Figure 8) and for the 
unreported 1,3ˊ-diindolylalkanes (17).32 
 
 
The paragraphs that follow will outline the major methodologies that have been employed in 
the synthesis of diindolylalkanes, followed by an update of the N-hydroxyalkylation of 
indoles. This background will serve as an introduction to our own research. 
 
2.1 Common methods for 3,3’-DIMs synthesis  
Commonly, diindolylalkanes are obtained from the electrophilic substitution of 
indole, substituted indoles or indolyl Grignard reagents (18) with aldehydes, ketones, α-
ketoacids, imines, iminium salts or nitrones (19).
33
 As shown in Scheme 3, this type of 
reaction can be catalyzed by protic acids (e.g. HCl)
34
 as well as Lewis acids (e.g. BF3 or 
AlCl3).
35
 
 10 
 
 
 
However, these methods require rather harsh acidic conditions, which are often incompatible 
with other sensitive functions present in the substrates.  
The discovery of the antibacterial and antitumor properties of DIM, stimulated many groups 
to develop alternative synthetic methods for the preparation of these molecules. Thus, at the 
beginning of the 21
st
 century, several methodologies for the synthesis of DIM and derivatives 
were reported by using catalysts including Ln(OTf)3,
36 
FeCl3,
37
 I2,
38
 montmorillonite clay 
K10,
39
 InCl3,
40
 In(OTf)3,
41
 CF3COOH,
42
 PPh3·HClO4,
43
 ion exchange resin,
44
 LiClO4,
45
 
CuBr2,
46
 H3PO4·(MoO3)12,
47
 Sc(F3CSO3)3,
48
 ZrCl4,
49
 (NH4)2Ce(NO3)6
50
 and La(PFO)3.
51
 
Unfortunately, most of these methods suffer from various disadvantages such as the use of 
expensive Lewis acids or preformed reagents, plus furnishing DIMs in extremely low or 
sometimes unspecified yields. Even when the desired reactions proceed, often more than a 
stoichiometric amount of Lewis acid is required because it tends to be deactivated by nitrogen 
containing reactants. In addition, long reaction times and tedious aqueous work-up are often 
required. Finally, none of these methods is environmentally friendly, since always an excess 
of harmful organic solvent or hazardous catalysts are employed. 
In view of the importance of diindolylalkanes, these problems were overcome to some extent 
by recently reported eco-friendly methods under solvent-free conditions or using ionic liquids 
as reaction medium.
52
 Among them, a particular mention deserves the methodology reported 
in 2008 by Hosseini-Sarvari.
52d
 His method, which employs a catalytic amount of ZnO under 
solvent free conditions, was successfully applied to a selection of aromatic aldehydes, 
furnishing the corresponding DIMs in good to excellent yields.  
 11 
 
The Hosseini-Sarvari work was, undoubtedly, inspiring for the beginning of our 
research.  
 
2.2 Common methods for indole-N-carbinols synthesis 
The direct N-alkylation and in particular N-hydroxyalkylation of indoles have not 
often been investigated probably due to the scarce nucleophilicity of the N-H functionality.
53
 
In addition, hemiaminals of N-heterocycles are labile materials which tend, under basic 
conditions, to fragment into formaldehyde and the corresponding amine;
54
 this behavior 
clearly justify why N-carbinols were not considered interesting until some hemiaminals 
demonstrated to possess anti-tumor activity.
55
 
As shown in Scheme 4, mostly of the methods so far reported for the preparation of indole-N-
carbinols, employ vigorous conditions with an overall yield very low .
56
 
 
 12 
 
 
3. RESULTS AND DISCUSSION 
In the beginning of our study, with the aim of searching a new protocol to compounds 
2 and inspired by recent the work of Hosseini-Sarveari,
52d
 indole (18a) was allowed to react 
with paraformaldehyde, under solvent free conditions, at 100 ºC in the presence of excess 
CaO. 
Monitoring the experiment by GC-MS, from the very beginning of the reaction (5 min), we 
surprisingly observed that the synthesis of the desired 2 was accompanied by the formation of 
other two indole derivatives: indole-N-carbinol (16a), usually obtained in strong basic 
conditions
56
 (cf. Scheme 4) and the novel dimeric derivative 17a (Scheme 5). 
 
 
Moved by these interesting observations, we decided to first investigate the N-
hydroxyalkylation of indole, studying all the parameters involved in the reaction with respect 
to 16a. We started exploring the role of the metal oxide, conducting the reaction in the same 
conditions but in the absence of oxide: any change occurred and the starting material was 
completely recovered. In like a vein, the reaction didn’t proceed at all at RT, both with or 
without the alkaline oxide. 
Fixing the reaction at 65 ºC showed to be the best temperature to obtain indole-N-carbinol 
with the best regioselectivity (Scheme 6), while higher temperatures directed the reaction 
towards dimers formation, as it will be explained in detail later. 
 13 
 
 
As shown in Table 1, the pivotal importance of the amount of metal oxide was also 
immediately evident; indeed, when the metal oxide was used in large excess, reactions 
proceeded rapidly (30 min) and smoothly, whereas the use of a catalytic or a stoichiometric 
amount was fruitless. 
 
We assume that the metal oxide may act as a multifunctional agent, contributing in 
association with the temperature to the depolymerization of paraformaldehyde into the free 
and highly reactive formaldehyde. In addition, it neutralizes the traces of formic acid 
produced during prolonged heating, which would be detrimental for the formation of N-
carbinols. 
To test if the metal of the oxide had any influence into the overall yields, we carried out the 
reaction employing other three different oxides: MgO, ZnO and TiO2. It is not surprising that 
the oxides possessing strongly electropositive cations (CaO and MgO) better activating the 
aldehyde, gave the best yields.  
We also believe that the oxide might induce a partial N-H abstraction of the indole, allowing 
the addition of the resultant N-anion to the highly reactive and activated formaldehyde. 
The use of a stronger base as potassium hydroxide unfortunately didn’t give any positive 
contribution: no traces of indole-N-carbinol were ever detected. A possible explanation is 
 14 
 
related to the thermal decomposition of indole-N-carbinol, which can regenerate indole and 
formaldehyde (Scheme 7).
56b
 
 
Different solvents were also studied in order to optimize the methodology. As the reaction is 
a typical nucleophilic addition, we focused our attention on DMSO, DMF, acetone and 
acetonitrile, strongly dissociating polar aprotic solvents, which tend to favor the attack at the 
indole nitrogen. As a matter of fact, no reaction improvement was evidenced by using THF or 
apolar solvents as toluene or hexanes (Table 2). Besides, polar protic solvents have been 
banned in order to avoid a nucleophilic competition or a reduction of the strength of our 
indole nitrogen. 
 
Overall, we noticed a sizable improvement of the yields when running the reaction in the 
presence of DMSO but because of the partial solubility of indole-N-carbinol in water and its 
instability at high temperatures, after work up only a small amount of 16a was recovered. 
Consequently, the conduct of the reaction under solvent-free conditions showed to be the best 
manner to obtain compound 16a in good yields. 
The hypothesis that the reaction, if successful with 18a would allow similar results while 
carried out with different indole derivatives, led us to conduct exploratory reactions with 
compounds 18b-19n. Almost all indole substrates were purchased from commercial sources, 
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apart from compounds 18i and 18j which were prepared in accord with literature
57
and 18c 
and 18h, prepared via Suzuky coupling.
58
 
As shown in Table 3, the developed protocol showed to be valid for substrates 18b-1k. 
 
 
In detail, the reactions carried out with compounds 18d-g gave the best results: thus, after two 
h, all the starting material resulted consumed, affording the corresponding 16 in 60-70% 
yield. Interestingly, products 16d-g were detected, although in low yields, even without using 
any alkaline oxide. This behavior, probably due to the presence of an electron-withdrawing 
substituent, (which helps the removal of the N-H proton, by reducing its pka), would confirm 
the surmise we previously made about the additional role of the metal oxide.  
With those subtrates carrying an electro-donating group at C-3, the yields were usually lower 
especially with compounds 18b and 18j which the corresponding 16b and 16j could be 
detected only on a mass spec analysis because they decomposed during work-up. 
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Unfortunately no reaction was observed with substrate 18l, 18m and 18n; in this case, we 
assume that the lack of reactivity might be related both to electronic and steric effects of the 
substituent. 
The optimized procedure was then extend to a series of aliphatic aldehydes with α-hydrogens 
(19); at this stage, the sole identifiable products were the N-alkenyl indoles 20, certainly 
derived from in situ dehydration of the corresponding 21 (Scheme 8). 
 
Running the same reaction with aromatic aldehydes (22) and ketones (23), no N-carbinol 
(Scheme 9 and 10) was ever observed; this result is not surprising if we take in account the 
reduced reactivity of aromatic aldehydes and ketones compared to aldehydes. 
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As advertised earlier, when 18a was allowed to react at 100 ºC (instead of 65 ºC) with 
formaldehyde or other aliphatic aldehydes, the N-carbinol formation resulted to be 
suppressed in favour of an approximately 2:1 mixture of the corresponding dimers 2 (major 
product) and 17 (Table 4). At 100 ºC but in the presence of an aromatic aldehyde, only the 
formation of dimeric product 2 was observed. Interestingly, with aliphatic and aromatic 
aldehydes, the reaction proceeded best in the absence of metal oxide, conferming once again 
the crucial role of CaO mainly for the activation of paraformaldehayde. All the reactions 
were conducted for 3.5h as longer times didn’t provide any yield increase. 
 
A temperature increase above 100 ºC also had no significant effect on yields or product 
distribution. No reaction occurred with ketones. 
As said all along this work, dimers of type 2 are known. However, the present methodology 
can be considered an alternative efficient route to the synthesis of these molecules. 
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By contrast, reports on the preparation of 1,3’-diindolylalkanes are rare or absent,59 
consequently we directed our attention to these new dimers (17a-e). 
An interesting yield improvement, especially of isomer 17a, was noticed when KOH 
was used instead of CaO. A possible explanation, apart from the stronger electropositivity of 
K
+
, might be the fact that, when indole-N-carbinol (generated at 65 ºC) is heated in the 
presence of KOH decomposes to regenerate indole and HCHO, which react again to afford 
both 3,3’- and 1,3’-diindolyl methane isomers. 
To gain a better comprehension of the reaction mechanism, we examined the possible 
role of compound 16a. It didn’t demonstrate to be a real intermediate in the formation of 17a; 
thus, when it was allowed to react with indole and CaO, only traces of the two isomers were 
detected (Scheme 11). 
 
We believe that two different pathways are involved in the formation of isomers 2 and 17. In 
particular, we observed they share the same known azafulvene salt 5, which can react further 
at the indole C-3 or N position to furnish 2 or 17, respectively (Scheme 12). 
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The different reactivity of long-chain aliphatic aldehydes and aromatic aldehydes seems 
plausibly related to their intrinsically diverse steric and electronic features, associated with 
the modest nucleophilicity of the indole nitrogen. 
Interestingly, isomers 2 and 17 could be easily distinguished not only by NMR analysis but 
also by EI-MS; indeed, compounds 17 all showed the formation of [M-116]
+ 
ion (RA = 100 
%), which comes from N-C cleavage; by contrast, for compounds 2 the formation of this ion 
was almost insignificant (RA = 5 %) compared to the fragment of m/z 245 (RA = 100 %), 
generated by loss of Z substituent. 
BIOLOGICAL STUDIES 
Materials 16 and 17 were purified at homogeneity before evaluating their cytotoxic 
activity. Exactly they were tested as proliferation inhibitors of the hepatoma cell line FaO 
against 1 as control. 
With respect compounds 16, substrates 16a, 16b, 16d and 16e have been the first compounds 
of choice in order to investigate the possible role of the C-3 substituent on the cytotoxic 
activity. FaO cells were treated with an increasing concentration of these compounds for 24 
hours as well as 1. The results indicated a dose-dependent decrease of cell viability, as 
measured by NRU, compared to control. In particular, the derivatives 16a, 16d and 16e were 
to four fold more potent than 1 in suppressing the viability of FaO cells showing IC50 values 
ranging from 100 µM to 200 µM (Figure 9). 
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                                   Figure 9. Cytotoxic activity of compounds 16a, 16b, 16d, 16e. 
Since preliminary evaluations of metabolic transformations
60
 did not evidence cellular 
formation of formaldehyde or other dimer derivatives, we suppose the cytotoxic activity of 
these compounds is related to other interactions. Indeed, further studies demonstrated that the 
mortality of FaO cells is associated with the inhibition of poly (ADP-ribose) polymerase 
(PARP).
61 
PARP is a nuclear enzyme which in physiological conditions is involved in damaged-DNA 
repair, so promoting cell recovery (Figure 10).
62 
Not surprisingly, it has been proved that inhibition of PARP results in a pro-apoptotic effect: 
consequently PARP inhibitors, as the potent 3-aminobenzamide,
63
 represent a new class of 
anticancer drugs. Such inhibitors stimulate the activation of caspase 3, a member of the 
cysteine-aspartic acid protease,
64
 which recognizes PARP as a substrate; subsequent cleavage 
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of PARP between Asp
214
-Gly
215
 determines loss of enzymatic activity
65 
and the resulting N-
terminal
 
and C-terminal PARP fragments accelerate apoptosis.
66 
 
 
 
                   Figure 10. Activity of PARP. 
 
In order to evaluate the possible apoptotic effect of our new derivatives, we determined the 
expression of the poly(ADPribose)polymerase (PARP) protein by western Blot analysis. 
The results shown in Figure 11 clearly indicate that, at the highest tested concentration, 1 as 
well as derivatives 2a, 2d and 2e caused an increase of the cleaved PARP protein in FaO 
cells, so inducing apoptosis. 
 
 
                         Figure 11. Western Blot analysis. 
 
 22 
 
Same investigations are in progress with the other indole-N-carbinol derivates 16c, 16f, 15g 
and 16k. 
In view of their in vivo application, we also tested the stability in acidic conditions of 
compounds 16a, 16b, 16d, 16e, 16f, 16g monitoring the experiments via NMR analysis. We 
observed that after the treatment with labeled HCl, the most stable compounds were 
derivatives 16e and 16f while the others produced an acidic reaction mixture consisting of 
dimers and others side products. All the other derivatives are now under investigation in 
similar experimental conditions. 
A cytotoxic evaluation (using the neutral red uptake assay) was also made on the new dimeric 
compounds 2a and 17a (Figure 12) which demonstrated to be twenty to four fold more potent 
than 1 (used as control) in suppressing the viability of FaO cells with IC50 value ranging 50 to 
100 µM after treatment with 2a and from 25 to 400 µM after treatment with 17a. 
Further studies are needed in order to determine the effect of the novel indole derivatives on 
the Akt pathway-mediated oncogenic signaling, possibly leading to changes in cell cycle 
progression and eventually apoptosis. 
 
Figure 12. Cytotoxic activity of compounds 2a and 17a. 
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5. CONCLUSIONS AND FUTURE WORK 
In conclusion, we have developed an economically and environmentally friendly 
catalyzer for simple and efficient synthesis of DIMs. The present methodology involves the 
use of CaO as a very inexpensive and easily available catalyst, requiring short reaction times 
and solvent-free conditions. Hence, it is a useful addition to the existing methods.  
In addition, we have synthesized a series of novel indole-N-carbinols and some 
unreported 1,3’-DIMs which were both subjected to preliminary biological studies in 
hepatocarcinoma FAO cells, showing similar or greater toxicity compared to the control 
(indole-3-carbinol). Consequently, the latter are potential anticancer molecules. 
Further efforts are actually in course to explore the role of the stereocentre in the biological 
activity of 1,3’-DIMs as well as studies in vivo both for compounds 2 and 17 are under 
process. 
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7. EXPERIMENTAL PROCEDURES 
Chemical general methods 
Unless otherwise stated, 
1
H and 
13
C NMR spectra were recorded at RT on a 300 MHz 
Varian spectrometer. Chemical shifts are reported in parts per million (ppm) on the δ scale 
using using tetramethylsilane as internal standard. Coupling constants, J, are in Hertz (Hz) 
and multiplicities are reported as “s” (singlet), “d” (doublet), “t” (triplet), “q” (quartet), “m” 
(multiplet), and “br” (broad). IR spectra were recorded in KBr or neat on Perkin-Elmer 1310 
spectrophotometer. Low resolution mass spectrometric experiments were carried out on a 
Saturn 2000 ion-trap coupled with a Varian 3800 gas chromatograph (Varian, Walnut Creek, 
CA) operating under EI conditions (electron energy 70 eV, emission current 20 µA, ion-trap 
temperature 200 ºC, manifold temperature 80 ºC, automatic gain control (ACG) target 21, 
000) with the ion trap operating in scan mode (scan range from m/z 40-400 at a scan rate of 1 
scan/sec). Micro-analysis for CHN were performed by a Carlo Erba 1106 Elemental 
Analyzer. Aliquot of 1 µL of solutions 1.0·10
-5
 M in chloroform have been introduced into 
the gas chromatographer inlet. A CIP Sil-8 CB Lowbleed/MS capillary column (30 m, 0.25 
mm i.d., 0.25 µm film thickness) was used. The oven temperature was programmed from 150 
ºC (held for 2 min) to 310 ºC at 30 ºC/min (held for 2 min). The temperature was then ramped 
to 350 at 20 ºC/min. The transfer line was maintained at 250 ºC and the injector port 30/1 
split) at 230 ºC.  
All areagents were purchased from commercial sources and used without further purification. 
Flash chromatography was performed on 60-120 mesh Aldrich silica gel. Analytic TLC was 
carried out on aluminum-backed Aldrich silica gel 60 F254 (0.25 mm) with fluorescent 
indicator. Spots were visualised with UV light and I2. 
Nuclear magnetic resonance analysis of acid stability 
Indole-N-carbinols 16a, 16b, 16d, 16e and 16f were dissolved in 0.75 ml of CD3OD. 
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To each solution were added 100 µL of deuterium-labeled HCl (35 wt. % in D2O, 99 atom % 
D) and nuclear magnetic resonance (NMR) spectra were recorded in a 300 MHz NMR 
spectrometer at room temperature at different time intervals. 
Biological general methods 
Rat FaO cell line was supplied by Interlab Cell Line Collection (Servizio 
Biotecnologie, IST, Genova, Italy). FaO cells were maintained in Dulbecco’s medium 
(DMEM plus Glutamax I, Invitrogen, S.r.l. Milano, Italy) supplemented with penicillin, 
streptomycin and 10 % heat-inactivated fetal calf-serum (FCS) (Invitrogen) in a humidified 
atmosphere of 5 % CO2/95 % air, at 37 ºC. 
Indole-3-carbinol and compounds 16a, 16b, 16d and 16e were dissolved in DMSO and were 
added to the culture media at different concentrations (cf. Figure 9). Control cells were 
treated with an equivalent amount of the solvent alone. 
Cell viability 
Cell viability was determined by the uptake of Neutral Red (NRU) by the lysosomes 
of viable cells. Determination of viability of the adherent cells by NRU assay was performed 
according to Borefreund and Puerner.
67
 
The value obtained for treated cells was expressed as percentage of the value obtained in 
control cells. All experiments were performed in triplicate and were repeated at least three 
times. 
Western Blot analysis 
Cell lysates, obtained by homogeneization with lysis buffer (1X PBS, 1 % IGEPAL, 
0.5 % sodium deoxycholate, 0.1 % SDS with 100µg/ml phenylmethylsulfonylfluoride, 300 
µg/mL aprotinin and 100 µg/mL sodium orthovanadate, all purchased from Sigma Aldrich), 
were incubated 30 min on ice and centrifugated at 12.000 rpm at 4 ºC, and the supernatants 
were recovered. Protein concentration was determined according to the method of Bradford
68
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using BSA as standard (DC Protein Assay, Bio Rad Laboratories, Hercules, CA). For 
immunoblotting analysis, equal amounts of proteins were electrophoresed on SDS 8 % 
polyacrilamyde gels. To ensure equivalent protein loading and transfer in all lanes, after gel 
electrotransfer onto nitrocellulose membranes (at 800 mA for 4 hours, 4 ºC), the membranes 
and gels were stained with 0.5 % (w/v) Ponceau S red (ICN Biomedicals) in 1 % AcOH, and 
with Coomassie blue (ICN Biomedicals) in 10 % AcOH, respectively.  
Before staining, gels were fixed in 25 % (v/v) isopropanol and 10 % acetic acid (Sigma). 
After blocking in TBS containing 0.05 % Tween 20 (Sigma) (TBS-T) and 5 % non-fat dry 
milk, overnight at 4° C, membranes were washed in TBS-T and incubated with the 
appropriate primary antibodies diluted in blocking buffer. The same membrane was used to 
detect the expression of PARP and Actin. Depending on the origin of primary antibody, 
filters were incubated with anti-mouse, or anti-rabbit horseradish peroxidase-conjugated IgGs 
(Santa Cruz Biotechnology). 
Immunoreactive bands were identified with chemiluminescence detection system, as 
described by the manufacturer (Supersignal Substrate, Pierce, Rockford, IL). For 
immunoblotting experiments, the rabbit polyclonal anti-poly(ADP-ribose) polymerase 
(PARP) (Cell Signaling Technologies, Beverly, MA) and mouse monoclonal anti-actin (clone 
AC-40) (Sigma-Aldrich, Milano, Italy) were used. 
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General synthetic procedure for the synthesis of compounds 16a-k 
A mixture of 18a (8.54 mmol), paraformaldehyde (10.25 mmol) and CaO (145.18 
mmol) was refluxed for the period indicated (TLC) at 65 ºC. After reaction, the crude mixture 
was washed with acetone and filtered through a pad of celite. The filtrate was concentrated 
under vacuum and purified through flash column chromatografy (silica gel), obtaining the 
desired product. 
Synthetic procedure for the synthesis of compound 17a 
A mixture of 18a (8.54 mmol), paraformaldehyde (10.25 mmol) and CaO (14.45 
mmol) was refluxed for the period indicated (TLC) at 100° C. After reaction, the crude 
mixture was washed with DCM and filtered through a pad of celite. The filtrate was 
concentrated under vacuum and purified through flash column chromatografy (silica gel, 
EtOAc/Hex 30 %), obtaining the desired product. 
General synthetic method for the synthesis of compounds 17b-e 
A mixture of 18a (8.54 mmol) and the appropriate aldehyde (10.25 mmol) was 
refluxed for the period indicated (TLC) at 100° C. After reaction, the crude mixture was 
concentrated under vacuum and purified through flash column chromatografy (silica gel), 
obtaining the desired product. 
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(1H-indol-1-yl)methanol (16a) 
 
After 30 min of reaction, work-up and flash column chromatography (EtOAc/Hex 30%) 
compound 16a was recovered as colorless thick oil in 65 %. 
1
H NMR (CDCl3): δ 7.62 (d, J = 7.8 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.25 (t, J = 7.8 Hz, 
1H), 7.20-7.16 (m, 2H), 6.53 (d, J = 3.3 Hz, 1H), 5.61 (d, J = 4.8 Hz, 2H) 
13
C NMR (CDCl3): δ 135.93, 128.80, 125.89, 121.24, 119.00, 118.42, 110.12, 109.06, 68.70  
EI/MS (%): 147 (55), 130 (4), 117 (100), 103 (1), 90 (40), 89 (45) 
IR (neat): v 3250, 2980, 1625, 1470, 1260 cm
-1 
Anal. calcd for C9H9NO: C 73.47, H 6.12, N 9.52; found: C 73.40, H 6.03, N 9.49 
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(3-methyl-1H-indol-1-yl)methanol (16b) 
 
 
After 30 min of reaction, work-up and purification via flash column chromatography 
(EtOAc/Hex 30%) compound 16b was obtained as thick oil in 55 % yield. 
1
H NMR (CDCl3): δ 7.59 (d, J = 7.5 Hz, 1H), 7.39 (d, J = 7.5 Hz, 1H), 7.27 (t, J = 7.5 Hz, 
1H), 7.19 (t, J = 7.5 Hz, 1H), 6.91 (s, 1H), 5.50 (s, 2H), 2.34 (s, 3H) 
13
C NMR (DMSO): δ 135.83, 128.79, 125.96, 121.21, 118.84, 118.53, 110.12, 109.56, 68.35, 
9.67  
IR (neat): v 3300, 2860, 1600, 1480, 1260 cm
-1
 
EI/MS (%): 161 (77), 144(8), 139 (100), 103 (10), 77 (12) 
Anal. calcd for C10H11NO: C 74.53, H 6.83 N 8.69; found: C 74.49, H 6.82 N 8.70 
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3-((o-methoxyphenyl)-1H-indol-1-yl)methanol (16c) 
 
After 30 min of reaction, work-up and purification via flash column cromatography 
(EtOAc/Hex 30%) 16c was recovered as a gummy product in 70 % yield. 
1
H NMR (CDCl3): δ 7.78 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 8.1 Hz, 
1H), 7.28-7.23 (m, 2H), 7.19 (t, J = 7.8 Hz, 1H), 7.04 (q, J = 8.1 Hz, 2H), 5.67 (s, 2H), 5.30 
(s, 1H), 3.85 (s, 3H) 
13
C NMR (DMSO): δ 156.33, 144.01, 135.66, 129.71, 128.13, 127.21, 123.70, 121.35, 
120.60, 119.97, 119.76, 111.70, 110.60, 68.78, 54.36  
IR (KBr): v 3410, 1650, 1420, 1260, 1130 cm
-1
 
EI/MS (%): 253 (25), 223 (100), 139 (100), 208 (42), 180 (26), 152 (20), 130 (8) 
Anal. calcd for C16H15NO2: C 75.89, H 6.38 N 5.53; found: C 75.90, H 6.33 N 5.52 
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Expanded 
1
H and 
13
C NMR of 16c. 
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1-(hydroxymethyl)-1H-indole-3-carbaldehyde (16d) 
 
After 2 h of reaction, work-up and purification via flash column chromatography compound 
16d was obtained as a white solid in 65 % yield. 
Mp: 101-103 ºC 
1
H NMR (DMSO): δ 10.06 (s, 1H), 8.47 (s, 1H), 8.21 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 8.1 Hz, 
1H), 7.47-7.36 (m, 2H), 6.92 (t, 1H), 5.73 (app d, 2H) 
13
C NMR (DMSO): δ 190.22, 145.64, 141.71, 130.09, 128.77, 127.86, 126.20, 122.65, 
116.77, 74.90 
IR (KBr): v 3350, 2980, 2850, 1725, 1660, 1280 cm
-1
 
EI/MS (%): 253 (25), 223 (100), 139 (100), 208 (42), 180 (26), 152 (20), 130 (8) 
Anal. calcd for C16H15NO2: C 68.57, H 5.14, N 8.00. Found: C 68.55, H 5.16, N 7.87. 
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1-(1-(hydroxymethyl)-1H-indol-3-yl)ethanone (16e) 
 
After 2 h of reaction, work-up and purification via flash column chromatography 
(EtOAc/Hex 30 %) compound 16e was obtained as a white solid in 60 %. 
Mp: 128-130 ºC 
1
H NMR (DMSO): δ 8.51 (s, 1H), 8.32 (d, J = 8.7 Hz, 1H), 7.75 (d, J = 8.7 Hz, 1H) 7.42-
7.25 (m, 2H), 6.84 (t, J = 7.5 Hz, 1H), 5.70 (d, J = 7.5 Hz, 2H), 2.57 (s, 3H). 
13
C NMR (DMSO): δ 218.51, 136.42, 127.65, 126.58, 122.93, 122.27, 121.56, 116.20, 
109.99, 69.61, 28.14  
IR (KBr): v 3400, 2850, 1715, 1660, 1420, 1300 cm
-1 
EI/MS (%): 189 (27), 174 (12), 146 (45), 116 (100) 
Anal. calcd for C11H11NO2: C 69.84, H 5.82, N 7.41; found: C 69.82, H 5.79, N 7.40 
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1
H and 
13
C NMR of 16e. 
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Methyl 1-(hydroxymethyl)-1H-indole-3-carboxylate (16f) 
 
After 2 h of reaction, work-up and purification via flash column chromatography (EtOAc/ 
Hex 30 %) compound 16f was obtained as a white solid in 70 % yield. 
Mp: 111-113 ºC 
1
H NMR (CDCl3): δ 7.96 (d, J = 7.5 Hz, 1H), 7.62 (s, 1H), 7.38 (d, J = 7.5 Hz, 1H) 7.20-7.14 
(m, 2H), 5.43 (s, 2H), 3.73 (s, 3H). 
13
C NMR (DMSO): δ 169.81, 137.02, 128.65, 126.41, 123.00, 122.47, 121.43, 116.12, 
111.67, 69.99, 62.84  
IR (KBr): v 3270, 1750, 1715, 1650, 1260, 1160 cm
-1
 
EI/MS (%): 205 (23), 175 (74), 161 (5), 144 (100), 116 (27), 89 (22). 
Anal. calcd for C11H11NO3: C 64.39, H 5.36, N 6.83; found: C 64.41, H 5.34, N 6.82 
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Expanded 
1
H and 
13
C NMR of 16f. 
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1-(hydroxymethyl)-1H-indole-3-carbonitrile (16g) 
 
After 2 h of reaction, work-up and purification via flash chromatography (EtOAc/Hex 30 %) 
compound 16g was obtained as a white solid in 67 % yield. 
Mp: 105-107 ºC 
1
H NMR (DMSO): δ 8.45 (s, 1H), 7.84 (d, J = 8.5 Hz, 1H) 7.75 (d, J = 8.5 Hz, 1H) 7.50-7.38 
(m, 2H), 6.93 (t, J = 7.2 Hz, 1H), 5.72 (d, J = 7.2 Hz, 2H) 
13
C NMR (DMSO): δ 141.87, 139.93, 132.55, 128.72, 127.44, 123.88, 121.07, 117.29, 89.26, 
74.81  
IR (KBr):  v 3300, 2860, 2250, 1600, 1480, 1260 cm
-1
 
EI/MS (%): 172 (45), 142 (68), 116 (100). 
Anal. calcd for C10H8N2O: C 69.77, H 4.65, N 16.28; found: C 69.76, H 4.65, N 16.29 
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3-((o-bromophenyl)-1H-indol-1-yl)methanol (16h) 
 
After 1 h of reaction, work-up and purification via flash column chromatography 
(EtOAc/Hex 30 %) compound 16h was obtained as a gummy product in 65 %. 
1
H NMR (DMSO): δ 7.93 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.73 (d, 
J = 7.8 Hz, 1H), 7.56 (t, J = 7.8 Hz, 2H), 7.39-7.24 (m, 3H), 6.61 (t, J = 7.2 Hz, 1H), 5.71 (d, 
J = 7.2 Hz, 2H) 
 13
C NMR (DMSO): δ 136.30, 134.95, 128.69 (x 2), 127.43, 127.07(x 2), 126.11, 124.69, 
122.61, 120.78, 120.13, 118.51, 109.68, 69.93  
EI/MS (%): 303 [M+2] (24), 301 (22), 271 (45), 194 (100), 116 (67), 77 (40) 
IR (KBr): v 3310, 1640, 1420, 1260, 1130, cm
-1
 
Anal. calcd for C15H12BrNO: C 59.80, H 3.99, N 4.65; found: C 59.77, H 4.00, N 4.62 
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Expanded 
1
H and 
13
C NMR of 16h. 
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(3-bromo-1H-indol-1-yl)methanol (16i) 
 
After 30 min of reaction, compound 16i was detected in the crude but it decomposed during 
purification. 
EI/MS (%): 227[M+2] (100), 225 (98), 197 (25), 195 (23), 116 (50), 89 (20) 
 
(3-iodo-1H-indol-1-yl)methanol (16l) 
 
As 16i, after 30 min of reaction compound 16l was detected in the crude but it decomposed 
during purification. 
EI/MS (%): 273 (100), 243 (88), 116 (65), 89 (23). 
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(2-methyl-1H-indol-1-yl)methanol (16k) 
 
After 30 min of reaction, work-up and purification via flash column chromatography 
(EtOAc/Hex 30 %), compound 16k was obtained as colorless thick oil in 57% yield. 
1
H NMR (CDCl3): δ 7.54 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.21 (t, J = 8.4 Hz, 
1H), 7.13 (t, J = 8.4 Hz, 1H), 6.81 (s, 1H), 5.38 (s, 2H), 2.28 (s, 3H). 
13
C NMR (DMSO): δ 141.59, 133.02, 130.96, 125.41, 124.48, 114.83, 105.56, 105.43, 64.95, 
19.04  
IR (neat): v 3310, 1610, 1480, 1260, cm
-1
 
EI/MS (%): 161(50), 144(16), 130 (100), 117 (5), 103 (20). 
Anal. calcd for C10H11NO: C 74.53, H 6.83, N 8.69; found: C 74.51, H 6.79, N 8.66. 
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Expanded 
1
H and 
13
C NMR of 16k. 
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3-((1H-indol-1-yl)methyl)-1H-indole (17a) 
 
After 3 h of reaction, work-up and purification via flash column chromatography 
(EtOAc/Hex 20 %), compound 17a was obtained as a colorless oil in 25 % yield. 
1
H NMR (400 MHz, DMSO): δ 11.15 (br s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 3.2 
Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H) 7.62 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 7.2, 1H), 7.60 (s, 1H), 
7.46 (d, J = 8.0 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.09 (t,  J = 7.2 Hz 
1H), 6.51 (d, J = 3.2 Hz, 1H), 5.63 (s, 2H) 
13
C NMR (DMSO): δ 136.39, 135.70, 128.87, 128.33 (x 2), 126.37, 124.88, 121.30, 120.85, 
120.42, 118.83, 118.60, 111.64, 114.04, 110.28, 100.33, 41.33  
EI/MS (%): 246 (100), 230 (3), 218 (5), 130 (90), 117 (78), 103 (19), 89 (23), 77 (21), 63 
(17), 51 (7). 
HRMS: calcd for C17H15N2H
+
: 247.1235; found: 247.1226. 
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Expanded 
1
H and 
13
C NMR of 17a. 
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TOCSY and COSY of 17a. 
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3-(1-(1H-indol-1-yl)propyl)-1H-indole (17b) 
 
After 3.5 h of reaction, concentration in vacuo and purification via flash column 
chromatography (EtOAc/Hex 20 %), compound 17b was obtained as light yellow oil in 38 % 
yield. 
1
H NMR (400 MHz, DMSO): δ 11.17 (s, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 2.0 Hz, 
1H), 7.62 (d, J = 7.9 Hz, 1H) 7.56 (d, J = 7.9 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 
8.0 Hz, 1H ) 7.20 (t, J = 8.0 Hz, 1H), 7.13 (t, J = 8.0 Hz, 1H), 7.09 (t, J = 7.9, Hz 1H), 6.94 (t, 
J = 7.9 Hz 1H) 6.52 (d, J = 7.9 Hz, 1H), 5.92 (t, J = 7.2 Hz, 1H), 2.52 (q, J = 6.5 Hz, 2H), 
0.93 (t, J = 7.3 Hz, 3H)  
13
C NMR (DMSO): δ 136.48, 136.07, 128.21, 126.62, 126.23, 123.30, 121.25, 120.95, 
120.46, 118.90, 118.71, 118.51, 115.30, 111.48, 110.31, 100.74, 53.88, 27.62, 11.39  
EI/MS (%): 274 (5), 258 (1), 245 (4), 158 (100), 143 (8), 130 (12), 117 (25), 89 (7) 
HRMS Calcd for C19H18N2H
+
: 275. 1548; found: 275.1547 
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1
H and 
13
C NMR of 17b. 
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COSY of 17b. 
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3-(1-(1H-indol-1-yl)hexyl)-1H-indole (17c) 
 
After 3.5 h of reaction, concentration in vacuo and purification via flash column 
chromatography (EtOAc/Hex 20 %), compound 17c was obtained as light yellow oil in 34 % 
yield. 
1
H NMR (400 MHz, DMSO): δ 11.10 (br s, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 2.0 
Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H) 7.54 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.33 (d, J 
= 7.8 Hz, 1H), 7.24 (t, J = 7.8 Hz 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.09 (t, , J = 7.8 Hz, 1H), 7.00 
(t, J = 8.0 Hz, 1H) 6.58 (d, J = 8.0 Hz, 1H), 5.64 (t, J = 7.5 Hz, 1H), 2.25-2.21 (m, 2H), 2.01-
1.97 (m, 4H), 1.55 (m, 2H), 0.96 (t, J = 7.0 Hz, 3H)  
13
C NMR (DMSO): δ 135.22, 134.00, 127.81, 126.59, 124.23, 123.78, 121.29, 121.48, 
120.87, 118.44, 118.13, 117.51, 115.22, 110.78, 110.35, 110.67, 59.80, 37.41, 32.54, 27.18, 
25.98, 12.87  
EI/MS (%): 316 (2), 245 (4), 218 (1), 200 (100), 156 (4), 130 (23), 117 (8) 
Anal. calcd for C22H24N2: C 83.54, H 7.59, N 8.86; found: C 83.51, H 7.63, N 8.85 
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3-(1-(1H-indol-3-yl)heptyl]-1H-indole (17d) 
 
After 3.5 h of reaction, concentration in vacuo and purification via flash column 
chromatography (EtOAc/Hex 20 %), compound 17d was obtained as light yellow oil in 22 % 
yield. 
1
H NMR (400 MHz, DMSO): δ 11.21 (br s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 1.8 
Hz, 1H), 7.57 (d, J = 7.6 Hz, 1H) 7.52 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.37 (d, J 
= 8.0 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 6.96 
(t, J = 8.0 Hz, 1H) 6.68 (d, J = 7.6 Hz, 1H), 5.21 (t, J = 7.7 Hz, 1H), 2.98 (m, 2H), 2.13-2.0 
(m, 6H), 1.89-1.82 (m, 2H), 0.89 (t, J = 7.7 Hz, 3H)  
13
C NMR (DMSO): δ 138.78, 136.05, 127.99, 126.67, 124.00, 123.54, 121.34, 121.18, 
120.69, 119.44, 118.24, 117.52, 115.29, 111.78, 110.99, 100.96, 60.00, 37.56, 32.45, 29.41, 
27.17, 25.88, 11.99 
EI/MS (%): 330 (3), 245(5), 214 (100), 200 (100), 156 (3), 143 (3), 130 (72), 117 (22), 103 
(2), 89 (3). 
Anal. calcd for C23H26N2: C 83.64, H 7.88, N 8.48; found: C 83.60, H 7.91, N 8.46. 
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3-[1-(1H-indol-3-yl)docecyl]-1H-indole (17e) 
 
After 3.5 h of reaction, concentration in vacuo and purification via flash column 
chromatography (EtOAc/Hex 20 %), compound 17e was obtained as light yellow oil in 5 % 
yield. 
1
H NMR (400 MHz, DMSO): δ 11.19 (br s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 2.0 
Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.53 (d, 
J = 7.9 Hz, 1H ), 7.39 (d, J = 8.2 Hz, 1H), 7.26 (t, = J = 8.2 Hz, 1H), 7.19 (t, J = 8.2 Hz, 1H), 
7.13 (t, J = 7.9 Hz, 1H), 6.97 (t, 1H), 6.68 (d, J = 8.2 Hz, 1H), 5.77 (t, J = 7.9 Hz, 1H), 2.85-
2.2.80 (m, 2H), 1.70-1.64 (m, 6H), 1.58-1.52 (m, 8H), 1.15-1.10 (m, 4H), 0.75 (t, J = 7.4 Hz, 
3H)  
13
C NMR (300 MHz, DMSO): δ 137.29, 134.98, 127.65, 126.59, 124.51, 123.88, 121.59, 
121.27, 120.86, 118.42, 118.22, 117.55, 115.27, 110.77, 110.35, 101.37, 59.34, 38.01, 32.94, 
29.70, 29.67, 29.63, 29.61, 29.60, 29.57, 27.18, 25.78, 11.82  
EI/MS (%): 400 (1), 285 (10), 245 (1), 207 (1), 156 (5), 130 (25), 117 (5). 
Anal. calcd for C28H36N2: C 84.00, H 9.00, N 7.00; found: C 83.96, H 9.04, N 6.98 
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CHAPTER 2:  
PREPARATION OF TRIS-OXAZOLES BUILDING BLOCKS FOR THE TOTAL 
SYNTHESIS OF TELOMESTATIN 
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1. INTRODUCTION 
Telomeres are non-coding regions of DNA located at the end of eukaryotics 
chromosomes.
1
 They consist of tandem repeats of short, guanine-rich sequences, exemplified 
by the human telomeric sequence (5’-3’)TTAGGG,2 which have the ability to fold into so-
called "guanine tetrads:" square planar arrangements of four guanines held together by 
Hoogsteen hydrogen bonds (Figure 1). Stacks of two or more guanine tetrads generate a so-
called "G-quadruplex." Monovalent cations, notably K
+
 and Na
+
, greatly stabilize G-
quadruplex structures, presumably by coordinating the carbonyl oxygens projecting toward 
the interior of a G-tetrad. 
 
 
Figure 1. G-tetrads and G-quadruplex structures. 
 
Telomeres play a critical role in maintaining chromosomal integrity; indeed, they protect 
chromosome ends from being erroneously recognized as damaged DNA, which would cause 
aberrant recombination or degradation by exonucleases.
3
 Interestingly, each cycle of 
replication in normal cells comports a shortening of DNA telomeres by 50-200 bases, as a 
consequence of the inability of DNA polymerases to fully replicate the ends of chromosomes 
(the end replication problem).
4
 Furthermore, normal cells lack an active mechanism for the 
maintenance of telomeric structures.
5
 Consequently, telomere length tends to progressively 
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decrease, and once it reaches a critically short length (the Hayflick limit),
6
 the cell enters a 
senescence state and fails to replicate further. This is a natural part of the cellular aging 
mechanism, which ultimately leads to apoptosis. 
 In sharp contrast, cancer cells are able to maintain their telomere length during a 
virtually infinite number of replication cycles.
7
 This conservation of telomeres is a feature of 
almost all malignant cells, and it is associated with their immortality.
8
 In 1984, Blackburn 
and co-workers discovered that the agent responsible for such maintenance of telomere length 
is an enzyme that they termed "telomerase".
9
  Telomerase is a multisubunit ribonucleoprotein 
that includes an RNA component and a catalytic subunit with specialized RNA-dependent 
DNA polymerase (reverse transcriptase, RT)
10
 activity, and it elongates telomeres by using its 
own intrinsic RNA template.
11
  This requires a non-folded telomeric DNA primer, meaning 
that the G-quartet structures described earlier must unravel for telomerase to operate. 
 Telomerase is normally expressed only in stem cells,
12
 while its expression is low or 
undetectable in normal somatic cells.
13
 However, it tends to be overexpressed in cancerous 
cells.
14
 Clearly, an agent capable of inhibiting telomerase activity may restore normal DNA 
replicative shortening (i.e., progressive loss of telomeres) in immortalized cancerous cells, re-
establishing normal aging mechanisms and, ultimately, apoptosis. 
In the past 30 years, substantial effort has been devoted to the identification of 
pharmacologically useful telomerase inhibitors.
15
 Such an endeavor has been hampered by 
the fact that the structure of telomerase remains elusive (no X-ray crystal structure is yet 
available), complicating the rational design of a suitable drug. On the other hand, it is known 
that the telomerase inhibition may be achieved by causing hybridization of its RNA template 
with suitable antisense oligonucleotides.
11b,16
 Alternatively, any mechanism that stabilizes G 
quadruplexes, thereby preventing their unfolding, would also inhibit the enzyme.
17 
(Figure 
2). 
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Figure 2. Inhibition of Telomerase by G-quadruplex stabilizing agents. 
 
The sequence of the eleven-base RNA template of telomerase is known;
18
 therefore, targeting 
the RNA primer with suitable anti-sense oligonucleotides is relatively straightforward. 
Unfortunately, such an approach may not be therapeutically viable, because some cancer cells 
possess an alternative mechanism for telomeres maintenance: the so-called Alternative 
Lengthening of Telomeres (ALT), which appears to be independent of telomerase and to 
involve recombination events.
19
 
 
1.1 G-quadruplex stabilizing agents as telomerase inhibitors 
The search for agents capable of stabilizing G quadruplexes has unveiled a number of 
small-molecule inhibitors of telomerase. Examples include cationic porphyrin 1,
20
 perylene 
2,
21
 fluorenone 3,
22
 acridine 4,
23
 ethidium derivative 5 (Figure 3).
24
 The inhibitory activities 
of these substances are in the micromolar range. For instance, the especially active porphyrin 
1 displays an IC50 = 0.63 µM. This is probably insufficient to warrant use as therapeutic 
agent. In addition the above compounds exhibit poor selectivity for telomerase; for instance, 
they inhibit Taq polymerase,
25
consequently arresting DNA synthesis.
26 
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Because telomerase is a specialized reverse transcriptase (RT), it is not surprising that the 
above compounds are also active against RT's associated with various retroviruses. To 
illustrate, porphyrin 1 inhibited the RT's from the Human Immunodeficiency Virus (HIV, the 
causative agent of AIDS) and Moloney Murine Leukemia Virus (MMLV) with IC50's equal to 
2.77 and 1.38 µM, respectively.
27
 Thus, the IC50 values of 1 toward a range of RT's are 
comparable, indicating that the compound is largely nonselective toward such enzymes. It 
will be sees shortly that, in contrast to 1 and congeners, telomestatin is an exceptionally 
selective inhibitor. 
A structural feature common to substances 1-5 is an extended planar chromophore, which 
can stack upon, or intercalate, the telomeric G-tetrads. Cationic species such as ethydium 
salts or protonated acridines may establish ionic bonds with the negatively charged phosphate 
groups present in DNA. Unfortunately, the structures of these agents seem to depart 
significantly from that which is normally considered a "drug-like" molecule.
28 
Furthermore, 
their poor selectivity translates into off-target activity, which is associated with toxicity. To 
complicate matters, telomerase inhibitors express their activity over a period of time that 
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encompasses a number of cell division cycles. Thus, they require days, perhaps weeks, to 
induce the desired telomere attrition. Consequently, a pharmacologically useful inhibitor 
must be active at doses well below the acute toxicity level. None of the foregoing compounds 
satisfy such a requirement.  
A major breakthrough in this area was the discovery of telomestatin (cf. 6, Figure 4),
27
 a 
polyoxazole natural product that proved to be the first potent (IC50=5nM) and highly 
selective inhibitor of human telomerase ever identified. Such valuable biological properties 
have generated a substantial demand for telomestatin as a uniquely useful probe of 
telomerase function.
27
 Unfortunately, the compound is very rare, and its supply precarious. 
 
More significantly, its poor aqueous solubility seriously hinders biological studies. A 
chemical synthesis of telomestatin that could also be adapted to the preparation of more 
water-soluble analogs, and that could grant access to congeners with an improved 
pharmacological profile, would clearly be exceptionally valuable. The present dissertation 
addresses a number of issues associated with a synthesis of 6 and it describes the preparation 
of two tris-oxazoles fragments of the natural product. 
The sections that follow will outline the major strategies that have been employed in 
the chemical synthesis of polyoxazole natural products, followed by a survey of the synthetic 
work on telomestatin that has appeared in the literature since its discovery. This background 
will serve as an introduction to our own research. 
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2. OXAZOLE-CONTAINING NATURAL PRODUCTS 
Beginning in the early 1990s, a large number of oxazole containing natural products 
were isolated from marine organisms. Many of these substances incorporate a single oxazole 
displaying a 2,4- or 2,5-disubstitution pattern (Figure 5). Examples of such mono-oxazole 
natural products include pimprinine (7), calyculin A (8) and rhizoxin (9). Some others display 
multiple oxazoles that may be directly linked (Figure 6), as in hennoxazole A (10), muscoride 
 
 
 
A (11), diazonamide A (12), ulupalides & congeners (kabiramides, halichondramides and 
mycalolides) 13 and of course 6, or separated by one carbon atom as the bangazole 14, or 
again by a two-carbon bridge as the siphonazole 15 (Figure 7).  
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All these compounds have attracted considerable interest from the synthetic community on 
account of their unusual structure, the challenge associated with a total synthesis, and the 
wide range of biological activities that they possess. 
Among bis-oxazole substance, hennoxazole 10, and its congeners, isolated from marine 
sponges of the genus Polyfibrospongia,
29
 showed exceptionally activity against herpes 
simplex virus 1 and peripheral analgesic activity comparable to that of indomethacin.
30 
Diazonamide A, 12, and related compounds, isolated from the colonial ascidian Diazonia 
chinensis, display potent in vitro activity against HCT-116 human colon carcinoma cells.
31
 
Muscoride A, isolated from the freshwater cyanobacterium Nostoc muscorum, displays 
modest, but distinct antibiotic activity against Bacillus subtilis and Escherichia coli.
32
 The 
trisoxazole macrolides: ulapualides, kabiramides, halichondramides and mycalolides, derived 
from marine sponges of the genera Hexabrancus,
33
 Halicondria,
34
 Pachastrissa
35
 and 
Mycale,
36
 exhibit antileukemic, antifungal and ichthyotoxic properties.
37
 As indicated earlier, 
the hepta-oxazole substance, telomestatin, is the most powerful and selective human 
telomerase inhibitor ever discovered. 
 
2.1 Discovery of telomestatin 
Telomestatin 6 was isolated by Shin-ya, Seto et al. in 2001 from Streptomyces 
anulatus 3533-SV4 in Bunkyo-ku, Tokyo.
38
 The compound was identified while screening 
for naturally occurring telomerase inhibitors using the telomeric repeat amplification protocol 
(TRAP). The planar structure of 6 (Figure 8) was elucidated by extensive 2D NMR analysis. 
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This effort revealed a unique macrocyclic architecture consisting of two methyloxazoles, five 
oxazoles and one thiazoline ring connected to each other in a 2,4 manner. The configuration 
of the sole stereogenic carbon present in the molecule could not be assigned by spectroscopic 
methods, and it was ultimately established through chemical synthesis.
38
  
 
The biosynthesis of telomestatin, although not yet elucidated, may be anticipated to 
involve the cyclization of a macrocyclic peptide composed of one cysteine, five serines and 
two threonine subunits as 16 (Scheme 1). The emerging heptaoxazoline 17 could then 
undergo oxidation furnishing telomestatin 6. 
 
 
 
2.2 Biological activity of telomestatin  
The inhibitory effects of telomestatin against telomerase, which was extracted from a 
lysate of human B lymphoma Namalwa cells, were evaluated by using a modified TRAP 
assay with the addition of an internal standard.
39
 The compound was found to be surprisingly 
potent, with an IC50 of 0.005 µM. However, and contrary to inhibitors 1-5, it proved to be 
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highly selective for telomerase, showing no activity against DNA polymerases such as Taq. 
A high degree of selectivity for telomerase was also unveiled when 6 was tested against other 
RTs. Thus, the activity against RT from HIV and MMLV was modest, with IC50 values of 
19.4 µM and 13.4 µM respectively38. The ratios of such IC50 values versus that for human 
telomerase are thus equal to 3880 (HIV) and 2680 (MMLV), signifying that telomestatin is a 
specific telomerase inhibitor. As a consequence, it will induce apoptosis in different human 
cancer cells.
40
 
In 2002, Hurley and coworkers experimentally proved that telomestatin selectively 
facilitates the formation of or stabilizes intramolecular G-quadruplexes, in particular, those 
produced from the human telomeric sequence d[T2AG3]4.
41
 More in detail, various 
concentrations of an oligomer with four repeats of the mentioned telomeric sequence were 
each incubated with increasing concentrations of telomestatin at 20 ºC for 30 min. At higher 
concentrations of telomestatin, the intensity of a new band with high mobility that 
corresponds to the intramolecular basket-type G-quadruplex was significantly increased, 
indicating that telomestatin promotes or stabilizes the formation of the intramolecular G-
quadruplex. Carrying out the same experiment with the mutated oligonucleotide d 
[T2AGAG]4, no conversion of the sequence to a G-quadruplex structure by telomestatin was 
observed. 
A number of groups have investigated structurally simplified analogs of 6, in the hope 
of identifying an agent that might be readily synthesized and as potent as the original.
42 
Recall that 6 itself is scarce, and that a total synthesis thereof is extremely challenging. 
Telomestatin analogs worthy of mention are compounds 18 and 19, synthesized by Pilch and 
Nagasawa, respectively. These molecules represent the most bioactive congeners of 
telomestatin yet uncovered.
43
  All share a hexaoxazole core and have exhibited cytotoxic 
activity against human cancer cells that are similar to — or greater than — those reported 
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previously for telomestatin.
44
 In addition, these compounds bind solely to the G-quadruplex 
form of nucleic acids under physiological conditions, with no detectable binding to duplex or 
 
triplex forms. However, while the anti-tumor effect of telomestatin is completely attributable 
to telomerase inhibition, compound 18a showed antiproliferative activity against both 
telomerase-positive and negative cells, meaning that its activity is independent of the 
telomerase status in cells.
44
 In addition, 18a can induce robust apoptosis within a short period 
of time (16h) which cannot be explained by telomerase inhibition that causes critically 
shortened telomeres only after many rounds of cell divisions. Consequently, the mode of 
action of 18a is independent of telomerase: the fact that the substance binds to the enzyme is 
immaterial as far as bioactivity is concerned. Considering the structural analogy, it is likely 
that the same may be true for substance 18b. 
By contrast, compounds 19 (a and b) not only show a high degree of selectivity but also 
inhibit the enzyme telomerase as greatly as telomestatin. Unfortunately not studies in vivo 
have been reported yet. 
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3. METHODOLOGY FOR OXAZOLE SYNTHESIS 
The challenge of achieving the synthesis of the natural products shown in Figure 6 
stimulated the development of new methodologies for the creation of oligo-oxazole systems. 
In this section, we shall first outline common methods for the preparation of oxazoles, and 
then review a number of oxazole-forming reactions that were developed specifically to 
address the problems associated with a synthesis of the foregoing compounds.  
 
3.1 Common methods for oxazole synthesis 
Oxazoles were discovered by Hantsch in 1887.
45
 Immediately thereafter, a number of 
methods were devised to prepare them, in the interest of studying their chemistry and 
properties. As shown in Scheme 2, common techniques for oxazole synthesis developed 
between the 1880's and the 1980's include: 
 
- Robinson-Gabriel reaction a).46 
- Oxidation of oxazolines b).47 
-  Rearrangement of N-acylaziridines followed by oxidation c).48 
- Rhodium-catalyzed additions of diazocarbonyls to nitriles d).49 
- Hantzsch reaction e).50 
- Base-catalyzed cyclization of propargyl amides f).51 
- Cornforth reaction g).52 
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3.2 Recently developed methods for oxazole synthesis 
Turning now to more recent methods, it is useful to distinguish two approaches to the 
creation of oligo-oxazole systems. Most of the procedures developed so far operate in such a 
manner that the carbon atom connected to position 4 of the template oxazole becomes the C-2 
atom of the new oxazole ring. We describe this approach as a 4  2' construction (Scheme 
3). 
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Significant strategies of this type have been disclosed by: 
G. Pattenden, details in session 3.2.1 
S. Yoo, details in session 3.2.2 
J.S. Panek, details in session 3.2.3 
P. Wipf, details in session 3.2.4 
C.J. Moody, details in session 3.2.5 
M.A. Ciufolini, details in session 3.2.6 
 
To the best of our knowledge, only two iterative approaches to oligo-oxazoles exist that 
operate in the opposite sense; i.e., in such a fashion that each new oxazole is assembled from 
a substituent connected to C-2 of a preexisting oxazole (Scheme 4). By analogy with the 
foregoing, we describe this second approach as a 2  4' construction. Such methods have 
been elaborated by: 
- P. Wipf, details in session 3.2.7 
- E. Vedejs, details in session 3.2.8 
-  
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3.2.1 The Pattenden chemistry  
In 1990, G. Pattenden and coworkers described the synthesis of a tris-oxazole 
fragment 20 of ulapualide A, 21 (Scheme 5).
53
 The synthesis started with the condensation of 
L-serine ethyl ester hydrochloride 22 with ethyl acetimidate hydrochloride 23.  
 
 
Oxazoline 24 so obtained was then oxidized with nickel peroxide in hot benzene, according 
to the method of Meyers et al., giving the corresponding mono-oxazole 25. The latter was 
advanced to 27 through acid chloride 26. Subsequent reaction with SOCl2 afforded an alkyl 
chloride that cyclized to oxazoline 28 upon exposure to AgOTf (Scheme 6). 
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Oxidation of 28 with NiO2 produced 29. Repetition of this sequence served to convert 29 into 
30 and finally into tris-oxazole 20. Compound 20 was thus prepared in an overall yield of 6% 
through a linear 14-step sequence patterned after a probable biogenetic pathway.  
This route was later improved by carrying out the oxidation of 28 using NBS and light 
(irradiation with a sun lamp),
54 
instead of NiO2. Alternatively, 28 can be converted into the 
corresponding phenylselenyl derivative 29, which upon oxidation to the selenoxide afforded 
20 through elimination.
55
 Finally 20 can be obtained in higher yield converting the alkyl 
chloride of 27 into the alkene 30 followed by bromination-dehydrobromination to the vinyl 
bromide 31 and cyclisation of the latter in the presence of copper (II) bromide and cesium 
carbonate
 
(Scheme 7).
55 
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A more convergent route to 20 was disclosed in 2000.
55
 This approach, based on the Wipf 
cyclization of β-hydroxy amides with the Burgess reagent,56 was successfully applied to the 
creation of ulapualides macrolactam core 32 (Scheme 8). 
 
 
Condensation of mono-oxazole carboxylic acid 33 with the mono-oxazole alcohol 34 led to 
the corresponding ester, which was then fully deprotected and cyclized to macrolactam 35. 
Cyclodehydration of 36 using the Burgess reagent, followed by oxidation of the resulting 
oxazoline in the presence of nickel peroxide, led to the target tris-oxazole macrolide 32. 
 
3.2.2 The Yoo chemistry  
It has long been known
57
 that a carbenoid arising through deazoniation of a 
diazocompound as 37 can be intercepted with a nitrile, leading to a transient nitrile ylide 38.  
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If group in 37 is a carbonyl substituent, cyclization to oxazole 39 will follow (Scheme 9). 
 
In 1992, Yoo et al. published a new approach to contiguous bis and tris oxazole systems as 
40 and 41 based on the foregoing chemistry (Scheme 10).
58
 Thus, the reaction of the TMS 
ether of pivalaldehyde cyanohydrin 42 with dimethyl diazomalonate 43 in the presence of 
dirhodium tetraacetate furnished 2,4-disubstituted oxazole 44. The action of LAH upon 44 
resulted in demethoxylation, presumably through conjugate addition of hydride and 
rearomatization through loss of MeOLi, and subsequent reduction of the ester to alcohol 45. 
Conversion of the latter to nitrile 46 was achieved in a 3-step procedure: Swern oxidation, 
oximation of the emerging aldehyde and oxime dehydration. 
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Nitrile 46 was resubmitted to a second cycle of the same sequence, leading to 40. A third 
cycloaddition, followed by reductive elimination and appropriate protection-deprotection of 
the hydroxyl groups, produced the ultimate 41, which was thus assembled in 16 steps with an 
overall yield of 3.3%. 
 
3.2.3 The Panek chemistry:  
It is apparent from the foregoing that the overall yields of polyoxazole products 
observed by Pattenden and Yoo are on the low side. The search for a more efficient 
alternative induced Panek and collaborators to research a Hantzsch-type oxazole construction 
for the preparation of tris-oxazole 47 (Scheme 11).
59
  
 
 
The Panek route started with the condensation of cinnamamide 48 with ethyl 
bromopyruvate 49, leading directly to oxazole carboxylic ester 50. Conversion of the latter to 
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the corresponding amide 51 set the stage for a second Hantzsch reaction that delivered bis-
oxazole 52. Upjohn-type dihydroxylation, oxidative cleavage of the diol, and reduction of the 
transient aldehyde was converted into 53. Amidation of the ester followed by protection of 
the primary alcohol provided silylated bis-oxazole 54, which was subjected to a third Hantsch 
reaction to give tris-oxazole 55. A final reduction of the ethoxycarbonyl group afforded the 
desired compound 47 in an overa ll yield of 26 % over 13 steps. 
 
3.2.4 The Wipf chemistry 
Wipf and Miller have explored a number of techniques for the preparation of highly 
functionalized oxazoles of the type found in many natural products. One such method greatly 
refined an older approach that entails the conversion of a β-hydroxy amide 56 into the 
corresponding oxazoline 57, followed by oxidation of the latter to an oxazole 58 (Scheme 
12). Specifically, the cyclodehydration of 56 by the use of the Burgess reagent
56
 proved to be 
superior to the traditional methods,
60
 furnishing very good yields and no side products.
61
 
Furthermore, it was determined that the customary reagent for the oxidative aromatization of 
oxazolines, nickel peroxide, performed poorly in the case of C-5 substituted substrates, 
whereas reaction of the oxazoline with BrCCl3 in the presence of DBU resulted in efficient 
aromatization. 
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Subsequent research revealed that oxazoline formation proceeded even more efficiently when 
DAST
62
 and its derivative Deoxo-Fluor
63
 was employed in lieu of the Burgess reagent in the 
cyclodehydration step.
64
 
Both DAST and Deoxo-Fluor are nucleophilic fluorinating agents that may be used, for 
instance, to convert alcohols to alkyl fluorides. A plausible mechanism for oxazoline 
formation may thus be envisioned as detailed in Scheme 13. Upon nucleophilic displacement 
of fluoride from the sulfur atom in 59, the OH group of β-hydroxy amide 56 is converted into 
a good nucleufuge (cf. 60). The carbonyl oxygen, acting now as a nucleophile, displaces the 
OH group thus activated, thereby producing the corresponding oxazoline 57. 
 
An important safety consideration associated with the use of the foregoing reagents is that the 
highly reactive DAST is notoriously shock sensitive and thermally unstable.
65
 Oxazoline 
formation by the use of DAST must be conducted at – 78 ºC to avoid local overheating and 
possible explosions. The less reactive Deoxo-Fluor is much safer to use and reactions with it 
may be carried out at – 20 ºC.   
Wipf and Miller also described major refinements of the classical Robinson-Gabriel oxazole 
synthesis (Scheme 14). First of all, a highly efficient oxidation of the β-hydroxy amide 56 to 
dicarbonyl compound 61 was achieved using the Dess-Martin periodinane.
66
 In addition, the 
combination of PPh3/I2 in the presence of Et3N allowed a mild, efficient cyclodehydration of 
61 to the ultimate oxazole.
67  
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Wipf successfully applied these protocols to the synthesis of hennoxazole A (10)
68
 and 
muscoride A (11).
69
 The total synthesis of 10, the first one ever reported, involved the 
condensation of amine 62 with acid 63 to afford amide 64. The latter was then oxidized and 
cyclized to give the corresponding bromooxazoline 65, which converged to ultimate 10 
through DBU-BrCCl3 treatment and TBAF desilylation (Scheme 15). 
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The construction of oxazole fragment 63 relied on the chemistry of Scheme 12, and it started 
with the oxymercuration – deoxomercuration of (Z)-2-butene-1,4-diol 66 to produce 67 
(Scheme 16). The latter underwent Claisen-Johnson rearrangement
70
 to provide 68. The ester 
was saponified and the acid was coupled with serine methyl ester 22 to afford amide 69, 
which underwent cyclodehydration with the Burgess reagent to give oxazoline 70. Oxidation 
of the latter to 71 was achieved with cupric bromide
71 
in the presence of DBU. O-desilylation 
and bromination of 71 yielded 72, which was finally coupled with vinyl stannane 73 and 
saponified to obtain the desired 63. 
 
 
 
The total synthesis of muscoride A (11) employed the modified Robinson-Gabriel oxazole 
construction delineated earlier in Scheme 14. The natural product resulted upon the coupling 
of 74 with 75 (Scheme 17), the preparation of which started with dipeptide 76, readily made 
by the condensation of N-Boc L-proline with L-threonine methyl ester hydrochloride. 
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Oxidation with DMP and cyclodehydration with PPh3/I2 delivered mono-oxazole 77. 
Hydrolysis of the methyl ester and coupling of the acid with L-treonine gave 78, which upon 
a second cycle of oxidation and cyclodehydration afforded bis-oxazole 79. Saponification 
followed by prenylation finally afforded the subtarget 74 (Scheme 18). 
 
 
 
 
3.2.5 The Moody chemistry  
Throughout the 1990's, Moody and coworkers greatly investigated and refined the scope of 
the Yoo methodology and introduced a variant thereof that entails the rhodium-catalyzed 
combination of nitriles with methyl 2-diazo-cyanoacetate.
49
 This leads to the formation of 4-
cyano-5-methoxyooxazoles, as exemplified in Scheme 19 through the reaction of 80 with 
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benzonitrile 81. The resultant 82 may be immediately subjected to a second round of the 
same chemistry, this time using dimethyl diazomalonate 43 as the carbenoid source, leading 
to bis-oxazole 83 in good yield. This was a significant advance, since then functionalized bis-
oxazoles could then be prepared in three steps form the starting diazo compound. 
An interesting property of 5-methoxyoxazoles is their ability to undergo hydride reduction to 
5-unsubstituted derivatives. Accordingly, reaction of 83 with LiAlH4 gave 84 in modest 
yield. 
 
 
3.2.6 The Ciufolini chemistry 
In 2003 Ciufolini and collaborators described an iterative approach to polyoxazole 
fragments
72
 and successfully applied it to the total synthesis of (-)-muscoride A (11),
73
 and 
other natural products.
74
 The method entails the reaction of a chloroglycinate such as 85 with 
a dimethylaluminum acetylide (prepared in situ), leading directly to oxazole 87 by way of 
alkynylglycinate 86 (Scheme 20). Compounds 85 are readily available by addition of generic 
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primary amides 88 to glyoxylate esters 89, followed by reaction of the resultant 90 with 
SOCl2, as detailed by Ben-Ishai.
75
 
 
 
Accordingly, the synthesis of 11 commenced with the union of (L)-N-Troc-prolinamide 91 
and ethyl glyoxylate, leading to 92 (Scheme 21). Exposure of 93 to the dimethylaluminum 
derivative of TMS acetylene and aqueous LiOH workup, directly afforded oxazole carboxylic 
acid 94. Four distinct transformations thus occurred in the process: substitution of the 
halogen, cyclization to an oxazole, ester hydrolysis and protiodesilylation. Acid 94 was then 
advanced to amide 95, which upon subjection to the same sequence afforded product 96. This 
material was converted into the final 11 by the method of Wipf.
69
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3.2.7 The Wipf chemistry  
In connection with studies toward diazonamide A (12), in 2001 Wipf devised an 
approach to poly-oxazoles construction
76
 that operates in a 2  4' fashion. Scheme 22 
illustrates the technique in the context of a synthesis of model diazonamide fragment 96. 
Indolic substrate 97 was coupled with N-Cbz-glycine then subjected to cyclodehydration with 
PPh3 and Cl3CCCl3 to afford compound 98. The latter was advanced to 99 through a 3-step 
procedure: hydrogenolysis, condensation with 2,2-diphenylpropanoic acid and N-Boc 
protection. Deprotonation of 99 with LDA triggered Chan rearrangement
77
 to 100, smoothly 
obtained in 78% yield. Cleavage of the Boc group, coupling with N-Cbz-valine, and 
traditional acid-mediated cyclodehydration of the resultant afforded fragment 96. 
 89 
 
 
3.2.8 The Vedejs chemistry 
In 2005 Vedejs developed a method for the assembly of poly-oxazoles starting from a 
C2-unsubstituted oxazole such as 101 (Scheme 23).
78
 Thus, deprotonation of 101 at C-2 
(BuLi, –78 °C), followed by reaction of the anion with hexachloroethane, produced 2-chloro 
oxazole 102, which reacted with the anion of tosylmethyl isocyanide (TosMIC) to afford 
isonitrile 103 through SNAr displacement of chloride. Subsequent treatment of 103 with 
glyoxylic acid monohydrate and K2CO3 resulted in formation of [2,4’]bis-oxazole 105, 
presumably via fragmentation of intermediate oxazoline 104. The emerging 105 served as the 
starting point of a second round of the same sequence, leading to tris-oxazole 106. A third 
round of the same chemistry yielded tetra-oxazole 107. It was further observed that the yield 
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of bis-oxazole 105 was higher when the conversion of 103 (isolable) into 105 was carried out 
in the same pot (72 % against 59 % for the stepwise procedure) of the previous step. 
 
 
 
 
4. SYNTHETIC STUDIES ON TELOMESTATIN 
As of this writing, two total syntheses of telomestatin (6) have been achieved. 
However, one of these appeared in the patent literature, and it is accompanied by scant 
experimental detail. In addition, two groups have described synthetic studies toward 6. 
Herein, we review published literature in this area. 
4.1 General considerations 
It is generally accepted that a convergent synthesis of a target molecule is more 
efficient than a linear one.
79 
In the case of telomestatin, an ideal approach would involve the 
union of two tris-oxazole fragments of essentially identical size as 108 and 109 (Scheme 24). 
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The lability of the thiazoline ring under various conditions suggests that this motif should be 
generated in the final step of the synthesis. In practice, fragments 108 and 109 would be 
coupled in the presence of a suitable condensing agent. The emerging 110 would undergo 
elaboration to oxazoline 111, which upon oxidation should furnish 112. Thiazoline formation 
would then complete the synthesis. 
Unfortunately, previous work revealed that it is not possible to achieve the aromatization of 
oxazolines such as 111 under any known oxidative conditions.
80
 This has forced the 
implementation of more or less circuitous routes to intermediates such as 113, which we shall 
refer to hereinafter as “pre-telomestatin” (Figure 9). The serious difficulties associated with 
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the assembly of 6 are especially apparent in the work of Takahashi and of Pattenden, both of 
which are reviewed in the sections that follow. 
 
 
4.2 The Yamada synthesis of telomestatin (Patent) 
It would seem that the first claim of a total synthesis of telomestatin appears in a 2002 
patent assigned to the japanese Taiho pharmaceutical company. This patent lists S. Yamada 
as the main inventor.
81
 Therefore, one may refer to the chemistry about to be discussed as the 
Yamada synthesis of 6. It should be stressed that the foregoing document provides scant 
experimental detail, especially concerning important details such as the precise coupling 
agents and conditions employed in certain key steps.  
The Yamada synthesis is based on the disconnection seen in Scheme 25. Fragments 114 and 
115 were described as being available by literature methods. Several references were 
provided in that respect; however, no precise experimental procedure is given in the patent. 
The coupling of 114 with 109 leading to diamide 115 is stated to be achievable using a 
variety of coupling agents, but preferably EDCI should be employed for the first 
condensation and diphenylphosphorylazide for the second one. The release of the acetal is 
described as occurring under acidic conditions (TFA, formic acid, HCl, H2SO4). 
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The key step of the synthesis is the cyclodehydration of 116 to form 117, an operation that 
apparently is best effected with a combination of PPh3, I2, and Et3N. Deprotection of the thiol 
with strong acid, possibly H2SO4, is alleged to result in direct formation of the thiazoline. 
 
4.3 The Takahashi synthesis of telomestatin. 
Takahashi et al. take the credit for the first total synthesis of telomestatin published in 
the peer-reviewed literature.
38
 This exercise also served to assign the absolute configuration 
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of the thiazoline ring as (R). The synthesis is based on the disconnection shown in Scheme 
26. 
 
 
Thus, the target molecule was envisioned to result upon the merger of tris-oxazole fragments 
118 and 119. 
Tris-oxazole 118 was prepared starting with the coupling of the known 2,5-disubustituted 
oxazoles 120 with 121
82 
in the presence of PyBroP (Scheme 27).  
 
The emerging bis-oxazole amide 122 was first subjected to cyclodehydration with DAST, 
and then oxidized with BrCCl3-DBU to furnish the desired 118.  
In the same fashion, tris-oxazole 119 (Scheme 28) was obtained by the condensation 
of amine 123 with acid 124. Thus, cyclodehydration of the emerging amide 125 using the 
Burgess reagent, followed by oxidation, afforded tris-oxazole 119.  
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Hydrogenolysis of the benzyl ester in 118 furnished 126 and N-deprotection of 119 gave 
fragment 127. 
Coupling of amine 127 with acid 126 provided hexa-oxazole amide 128 (Scheme 29). Acid 
cleavage of both the N,O-acetonide and N-Boc group in 128, followed by saponification and 
finally macrolactamization, gave diamide 129. All attempts to effect cyclodehydration of 
diamide 129 using DAST or the Burgess reagent failed: the only detectable product was pre-
telomestatin 113.  
An alternative oxidation of the alcohol 129 to an aldehyde and Robinson-Gabriel 
cyclodehydration of the resultant also failed. In light of results later disclosed by Pattenden,
80
 
as well as observations recorded in the course of our own research (vide infra), it is possible 
that this was due to fact that the aldehyde could never be secured.  
Ultimately, Takahashi et al. achieved formation of the seventh oxazole by elaboration of the 
undesired product 113 according to the method reported by Shin et al.
83
 Thus, compound 
113, best obtained by mesylation / elimination of 129, was treated with NBS in DCM-MeOH 
to afford 4-methoxyoxazoline 130. Elimination of MeOH with with camphosulfuric acid 
converted 130 into the desired heptaoxazole 131. Finally, thiazoline formation was carried 
out in 20 % yield by reaction of 131 with PPh3(O)-Tf2O. 
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 97 
 
4.4 The Moody formal synthesis of telomestatin 
A formal total synthesis of 6 was announced in 2010 by Moody and coworkers.
84
 
Although the Moody approach envisioned essentially the same building blocks employed by 
Takahashi (cf. 118 and 119 in Scheme 25 with 132 and 133 in Scheme 30), the two routes 
differ for the chemistry utilized to manufacture the oxazole rings. Not unexpectedly, the 
Moody synthesis is based on the reaction of nitriles or amides with diazocarbonyl compounds 
in the presence of catalytic amounts of rhodium(II) complexes. 
 
 
 
The synthesis of fragment 133 started with the protected cysteine carboxamide 134 (Scheme 
31), which underwent smooth carbene N-H insertion upon treatment with methyl 
diazoacetoacetate 43 in the presence of Rh2(OAc)4. Ketoamide 135 was thus obtained as a 
mixture of diastereoisomers. Cyclodehydration of 135 using the Wipf-Miller protocol
67
 
delivered oxazole 136 in excellent overall yield. Treatment of the latter with ammonia 
generated carboxamide 137, which was subjected to a second round of the same chemistry to 
afford bis-oxazole 138. Ester 138 was then converted into the corresponding nitrile 139, and 
the latter was combined with diazoaldehyde 140, leading to tris-oxazole 133. 
Three rounds of the same chemistry were also used to construct tris-oxazole 132 (Scheme 
32). Thus, nitrile 141, prepared from the serine-derived methyl ester, was directly converted 
into oxazole 142 by reaction with 140 in the presence of Rh2(NHCOC3F7)4. 
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Ammonolysis of the ester and dehydration provided nitrile 143, which participated in a 
second round of the above sequence to afford bis-oxazole 144. A third cycle of the same 
chemistry provided nitrile 145 and finally the required tris-oxazole 132. 
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Compounds 133 and 132 were advanced to amine 146 and acid 127, respectively, and the 
latter were coupled in the presence of HBTU (Scheme 33) to give hexa-oxazole 147, which 
was fully deprotected and subjected to macrolactamization using once again HBTU as the 
condensing agent. Dehydration of the resultant 129 afforded enamine 113, already reported 
by Takahashi and coworkers. Because these researchers have already converted 113 into 6, 
the Moody route to telomestatin can be considered as a formal synthesis of the natural 
product. 
 
 
4.5 Synthetic studies toward telomestatin 
4.5.1. The Shin approach. 
In 2003, Shin disclosed a synthetic study toward 6 that introduced a method for oxazole 
assembly that was ultimately key to the Takashi and the Moody syntheses.
85
 Shin's study 
focused on the construction of fragments 148 and 149 (Scheme 34). Material 148 was 
obtained starting from the protected diserine peptide 150 which was converted into enamine  
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151 through mesylation followed by dehydration (Scheme 35). Subsequent bromination with 
NBS in MeOH afforded 152, which cyclized to oxazoline 153 in the presence of Cs2CO3. 
Aromatization to 154 occurred upon exposure to camphorsulfonic acid (CSA), which 
promoted elimination of MeOH. Appropriate deprotection manoeuvres converted 154 into 
155 and 156. These were coupled and the emerging 157 was advanced to 148. 
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The same approach performed equally well with protected serine-threonine dipeptides 158 
and 159 as the substrates (Scheme 36). Thus, 158 was readily converted into oxazole 160 and 
159 into oxazole 161. Compounds 160 and 161 were advanced to amine 124 and acid 162, 
respectively, and the letter coupled in the presence of BOP furnishing amide 163. 
Consecutive β-elimination of 163 with MsCl/DBU, followed by bromination with NBS and 
cyclization with Cs2CO3 gave tris-oxazole 164 which was subjected to saponification and 
esterified once again to afford tris-oxazole 165. Removal of the isopropyl group and O-
protection finally converted 165 in the desired 149. 
 
Ester 148 was hydrolyzed to give 166 almost quantitatively and compound 149 was N-
deprotected to afford 167. The union of the acid with the amine under the influence of BOP 
gave the hexa-oxazole 168 (Scheme 37). This constitutes the first polyoxazole related to 6 
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ever to be described in the literature. Full deprotection and cyclization produced the novel 
diamide 169, which represents the most advanced stage of the Shin research to date. 
 
 
4.5.2 The Pattenden approach. 
In 2008, Pattenden and coworkers reported interesting results of investigations aiming 
to reach telomestatin through the merger of tris-oxazoles 170 and 171 (Scheme 38).
83
 
 
 
The requisite fragments were prepared in accord with Wipf,
64
 as shown in Schemes 39 and 
40. The construction of 170 started with the coupling of amine 155 with acid 172. The 
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emerging bis-oxazole amide 173 was then subjected to cyclodehydration with DAST to 
obtain oxazoline 174, which was aromatized using BrCCl3 in the presence of DBU. 
 
 
 
An analogous sequence was employed to prepare building block 171. Thus, condensation of 
acid 175 with amine 124 produced amide 176, which was elaborated to the final 171 via 
oxazoline 177. 
 
Release of the N-protecting group in 170 and saponification of the methyl ester in 171 
afforded the amine 178 and carboxylic acid 179, respectively (Scheme 41). These were 
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united in the presence of EDC-HOBt-NMM to give amide 180, which was fully deblocked 
and subjected to macrolactamization to furnish compound 181.  
 
Hydrogenolysis of the benzyl ether, followed by treatment with DAST, converted 181 into 
the corresponding oxazoline 182. Unfortunately all attempts to oxidize 182 to the 
heptaoxazole 183 failed. Among the various reagents examined for that purpose, nickel 
peroxide, DDQ, and BrCCl3 had virtually no effect upon the substrate under gentle conditions 
(recovery of unchanged 182). Under more forcing conditions, conversion into an intractable 
mixture of products resulted.  
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Attempts to obtain aldehyde 184 by oxidation of 181, e.g., with PDC, were fruitless, 
disallowing the investigation of a Robinson-Gabriel approach to 183. While no comment is 
offered with respect to the failure of this oxidation step, our own results suggest that 
overoxidation to an oxazole-2-carboxamide may have occurred (vide infra). Interestingly, 
when compound 181 was treated with DMP immediately followed by PPh3, 1,2-
dibromotetrachloroethane, di-tert-butylpyridine, and then DBU, in an attempt to induce in 
situ oxazole formation from a presumed transient aldehyde, enamine 185 was obtained as the 
sole characterizable product. This material clearly resulted from dehydration of 181.  
Attempts to reach 183 by conversion of 181 to vinyl bromide 186 by treatment with Br2-
Et3N, which could have cyclized to the oxazole in the presence of Cs2CO3 (Scheme 42), also 
met with failure. 
 
 
An alternative route based on a Hantsch-type oxazole assembly also produced 
disappointing results. Briefly, tris-oxazoles 187 and 188 were easily prepared and readily 
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coupled to provide amide 189, which was easily advanced to ketone 190 (Scheme 43). 
Unfortunately 190 resisted all attempts to convert it into bromoketone 191 as a prelude to a 
possible Hantsch cyclization to telomestatin. 
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5. AN ALTERNATIVE APPROACH TO TELOMESTATIN 
The objective of this research was to devise a technique that might resolve the problems 
associated with the aromatization of oxazoline intermediates on the way to pre-telomestatin 
(see sections 4.3 and 4.5.2 for a thorough discussion). We surmise that all such obstacles 
derive from an increase in ring strain incurred upon oxidation of 192, whereupon the atoms 
labeled with an asterisk progress from an sp
3
 to an sp
2
 hybridization state (Scheme 44). 
Consequently, an artifice must be conceived to circumvent these difficulties. 
 
Exploratory studies in our group suggest that attempts to aromatize 192 often result in 
fragmentation / elimination of the oxazoline and consequent formation of a "Takahashi-type" 
intermediate such as 194, which then undergoes further oxidative degradation to a complex 
mixture of products (Scheme 45).  
 
 108 
 
A possible remedy for this problem envisions the introduction of appropriate substituents, Z 
and G, on substrate 195 (Scheme 46). Initially, group G must be a poor nucleofuge to avoid 
possible eliminations. At the same time, it should enable the formation of a C–O bond, 
leading to oxazoline 196, at which stage, G must be turned into a good leaving group. The 
appropriate choice of substituent Z (Z ≠ H) would now enable the simultaneous departure of 
G and Z, leading to oxazole 193, again with no opportunity for formation of 194.  
 
For instance, Z could be a carboxy group and G a sulfur-based functionality (cf. 197). As 
seen in Scheme 47, this would enable oxazoline formation (cf. 198) through a Pummerer-type 
cyclization,
86
 and aromatization via decarboxylative desulfonylation (cf. 199).
87 
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Alternatively, the aromatization could be carried out with an oxazoline embedded in a 
slightly larger ring, which would be less sensitive to the increase in angle stain during 
formation of pre-telomestatin. A possible solution inspired by recent developments in peptide 
chemistry
88
 was conceived as detailed in Scheme 48. The macrocyclic motif would be created 
in the form of thioester 200, which upon Cornforth-like oxazole formation
64
 should produce 
201. Release of the Boc protection in 201 is likely to trigger S  N acyl migration (cf. 202), 
thereby delivering the desired pre-telomestatin.  
It is recognized that a sulfur atom, by virtue of the unusually long C–S bonds (1.8 Å) and its 
is isosteric with a pair of carbon atoms.
89
 Consequently, macrocyclic thiolactone 201 displays 
a ring that, in a formal sense, contains the equivalent of three additional C / N atoms relative 
to macrolactam 192. This may well be sufficient to promote an otherwise very problematic 
aromatization. 
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The implementation of the first strategy requires fragments 204 and 205 (Scheme 49). Full 
deprotection and condensation to these would generate diamide 206, which would then be 
processed as described earlier in Scheme 47 to produce 207. This would be followed by 
deblocking of the sulfur functionality and creation of the final thiazoline ring.  
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The second approach requires tris-oxazoles 208 and 119, which would be merged to yield 
thiolactone 209 (Scheme 50). The latter could advance to heptaoxazole 201 either through a 
Swaminathan reaction (treatment with TMSOTf and BH3Me2S)
90 
or by a more classical 
cyclodehydration of the Wipf
61 
or Robinson-Gabriel type.
67
 Subsequent N-deblocking should 
trigger an S  N acyl migration leading to 203, which would be processed on to 
telomestatine as reported by Takahashi. 
 
 
It will be recalled that fragments of the type 205 (cf. 119, 133, 149, 171) are already known. 
In the following section, we will describe first the preparation of fragment 119, which was 
elected as appropriate for either routes, then we will focus on the synthesis of fragments 204 
and 208 which, on the opposite, are not reported. 
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5.1 Preparation of the known tris-oxazole fragment 119 
Tris-oxazole 119 was prepared using the same building blocks reported by 
Takahashi
40
 (cf. Scheme 28) but their specific preparation resulted to be different. 
Thus, Takahashi prepared amine 124 following the Shin methodology
85
 and acid 123 using 
the Wipf modified Robinson-Gabriel reaction (cf. Scheme 14). 
Differently from Takahashi, we prepared both fragments 124 and 123 according to Wipf 
chemistry but favoring the use of the Deoxo-Fluor reagent, followed by treatment with 
BrCCl3/DBU, for the oxazole formation. The route leading to amine 124 is shown in Scheme 
51. Commercial N-BOC L-threonine, was O-protected with a TBS group (cf. 210) and then 
coupled with L-serine methyl ester hydrochloride in the presence of EDCI and HOBt. The 
corresponding dipeptide 211 was then treated with Deoxo-fluor at – 15 ºC and the emerging 
oxazoline 212 was directly oxidized to oxazole 213 with BrCCl3 and DBU. Removal of the 
silyl protecting group was achieved using a commercial 1M solution of TBAF in THF, 
providing 214 in quantitative yield. Finally, deprotection of the amino group was carried out 
using commercial 4M HCl in anhydrous dioxane furnishing ammonium salt HCl 124 in 
quantitative yield.  
 
It is worthy of mention that all along this work, anhydrous 4M HCl was preferred to the more 
commonly used TFA/DCM mixture, in that it afforded generally better yields, as well as 
simplifying the workup procedure. Removal of dioxane under vacuum sufficed to obtain 
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clean hydrochloride salts, while reactions run with TFA afforded products of inferior quality. 
The reasons for this remain unclear.  
Acid 123 was synthesized following the same general method, but starting with commercial 
L-threonine methyl ester hydrochloride and cysteine derivative 215 (Scheme 52). 
Condensation of the two in the presence of EDCI and HOBt gave dipeptide 216, which was 
cyclized with Deoxo-Fluor to afford oxazoline 217. The latter was then aromatized to the 
corresponding oxazole 218. Saponification under basic conditions released acid 123. 
 
To condense amine 124 and acid 123 we used EDCI in association with HOBt, while 
Takahashi employed PyBrop-DIEA. Dehydrative cyclization, followed by oxidation finally 
converted 125 into 119 (Scheme 53). 
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5.2 Preparation of compound 220 and attempted formation of tris-oxazole 204. 
A particularly convergent avenue to tris-oxazole fragment 204 entails the merger of 
aminoalcohol 155 with acid 219 (Scheme 54). Segment 155 is known,
85
 while 219 is not. A 
plausible synthesis of 219 may be charted from serine methyl ester and the unknown acid 
220, through coupling, oxazoline formation, and aromatization. A less convergent approach 
might involve the union of 220 with bis-oxazole 221, protected forms of which are known.
91
 
In either case, one would have to employ 220 as a key building block. The synthesis of this 
carboxylic acid thus became our first objective. 
 
Hydrogenation of dimethyl oxyminomalonate
92
 (cf. 222, Scheme 55) over Pd/C, according to 
the procedure of Nolan,
93
 required two days to complete, but it produced 223 in 92 % yield. 
Hydrogenation over Pd(OH)2/C (Pearlman catalyst)
94
 proceeded twice as fast, affording 223 
also in 92 % yield after only 24 h. Subsequent N-Boc protection gave the unreported 
carbamate 224 as a colorless oil, which solidified to a crystalline white solid upon cooling. 
Interestingly, 224 was obtained in higher yields when reduction and N-Boc protection were 
carried out in the same pot: upon completion of the hydrogenation step (NMR and TLC 
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monitoring), Boc2O was added to the reaction mixture, and after stirring at room temperature 
for 2 h, the desired 224 was retrieved in 79 % yield vs. 52 % yield for the two-step procedure.  
 
 
 
The emerging 224 was C-alkylated with PhSCH2Cl
95
 in DMF and in the presence of NaH 
(60% dispersion in mineral oil). The alkylation reaction was slow, requiring overnight stirring 
to achieve a 35% yield of the yet unreported 225 as a colorless oil which solidified to a waxy 
white mass on standing. Variable quantities of starting materials (typically about 20%) 
remained unreacted. Attempts to force the reaction to completion, by operating at higher 
temperatures (up to 80 
o
C), and / or by allowing longer contact times, failed to improve 
yields. Likewise, conduct of the reaction in MeOH using MeONa as the base had no effect 
upon overall efficiency. 
The last step of the sequence entailed the selective hydrolysis of only one of the two ester 
functions in 225. This operation had to be carried out carefully (constant monitoring of the 
progress of the reaction by TLC) using one stoichiometric equivalent of LiOH·H2O over a 
brief reaction time (≈ 3h). Under these conditions, an essentially 1:1 mixture of the desired 
acid 220 (a thick yellow oil) plus unreacted 225 was recovered. Fortunately, the two were 
readily separated by an acid/base extraction. 
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Attempts to force the above saponification reaction to completion, either by allowing a longer 
contact time or by using more than 1.0 equiv of base, resulted in double hydrolysis followed 
by decarboxylation. The unreported compound 226 (Figure 10) was thus retrieved as the sole 
discernible product in about 50-60 % yield, the balance of the crude reaction mixture being 
largely diester 225. Substance 226 represented a synthetic dead end and it was not thoroughly 
characterized. 
 
The above difficulties notwithstanding, the present route to 220 was deemed to be 
satisfactory at this juncture. Indeed, sufficient material was now available to explore the 
coupling of 220 with serine derivatives, in the interest of producing an ultimate oxazole such 
as 219.  
The coupling of acid 220 with serine methyl ester hydrochloride was first attempted using 
common condensing agents such as EDCI or DDC in the presence of HOBt (Scheme 56). 
Unfortunately, the desired product 227 was never observed. Instead, compound 220 
underwent decarboxylation to give the methyl ester of acid 226. Attempts to convert 220 to 
the corresponding acid chloride were also fruitless: exposure to SOCl2 resulted in the 
formation of an intractable mixture of compounds.  
 
 
The failure of 220 to undergo coupling with methyl serinate discouraged us from attempting 
the even more challenging condensation with bis-oxazole 221. Instead, we opted to explore 
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an alternative strategy to reach 219. As delineated in Scheme 57, the target 219 could be 
prepared by alkylation of oxazole substrate 231 with PhSCH2Cl. In turn the yet unknown 231   
seemed to be available by oxidation of the known 228 to acid 230, followed by esterification.  
 
Unexpectedly, the conversion of 228 into 229 proved to be exceedingly problematic. 
Oxidizing agents such as PCC,
96
 DMP,
66
 and DIB / TEMPO,
97
 promoted overoxidation 
(Scheme 58) of the substrate to white, crystalline compound 232, which appears to be 
unknown, and that was partially characterized by 
1
H and 
13
C NMR spectroscopy as well as by 
mass spectrometry (vide infra). 
 
By contrast, oxidation of 228 under Parikh-Doering
98
or Swern
99
 conditions afforded complex 
mixtures of products, seemingly as a result of the reactivity / instability of aldehyde 229. 
All such difficulties induced us to abandon this approach and refocus on the second strategy. 
 
5.3 Merger of fragments 155 and 233: preparation of tris-oxazole 208. 
The "thiolactone" approach to telomestatin required fragment 208, which may be 
manufactured from aminoalcohol 155 and acid 233 (Scheme 59). Compound 155 is known,
85
 
while 233 is not.  
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The preparation of 233 started with the known condensation of diethyl nitroacetate (cf. 234) 
with triethyl ortoformate
100
 in the presence of Hunig’s base and TiCl4, leading to racemic 
product 235 in excellent yield (Scheme 60). Hydrogenation of the latter in MeOH over Pd/C 
(overnight stirring at atmospheric pressure) furnished amine 236 in 84 % yield. The 
subsequent N-Boc-protection was best carried out in dioxane in the presence of sat. aq. 
NaHCO3, while the saponification of the emerging 237 to afford acid 238 occurred best in 
MeOH in the presence of LiOH·H2O. 
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The synthesis of oxazole 241 proceeded with the coupling of racemic 238 with enantiopure 
serine methyl ester hydrochloride in the presence of DCC and HOBt, affording the expected 
1:1 mixture of diastereoisomers of dipeptide 239. Stirring 239 with Deoxo-Fluor at – 20 ºC 
for 1h resulted in complete conversion into the corresponding oxazoline 240, which without 
further purification was advanced to the oxazole 241 with BrCCl3 in the presence of DBU. 
Subsequent treatment with methanolic LiOH·H2O overnight afforded acid 233 as a white 
solid. 
Coupling of amine 155 with acid 233 was then successfully performed in the presence 
of DCC and HOBt (Scheme 61) to give amide 242. Cyclization of 242 with Deoxo-Fluor 
afforded the corresponding oxazoline 243, which without further purification was advanced 
to the desired 208. 
 
  
 120 
 
6. CONCLUSIONS AND FUTURE WORK 
This research has established a route to a key tris-oxazole fragment required for the 
exploration of the “thiolactone” avenue to telomestatine. Such an objective is actively being 
pursued in the Ciufolini group and it will hopefully lead to a full total synthesis before long. 
The preparation of 208 described herein is straightforward, reasonably efficient, and readily 
scalable. Indeed, gram quantities of 208 have been accumulated since the completion of the 
studies detailed here. 
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8. EXPERIMENTAL PROCEDURES 
Unless otherwise stated, 
1
H (300 MHz) and 
13
C NMR (75 MHz) spectra were recorded at RT 
on a Brukel model AVANCE II
+ 
300 spectrometer using deuterated chloroform (CDCl3) as 
solvent.  
Chemical shifts are reported in parts per million (ppm) on the δ scale using the solvent 
residual peak as internal standard. Coupling constants, J, are in Hertz (Hz) and multiplicities 
are reported as “s” (singlet), “d” (doublet), “t” (triplet), “q” (quartet), “quint” (quintet) “dd” 
(doublet of doublets), “dt” (doublet of triplets)“m” (multiplet), “app” (apparent) and  “br” 
(broad). IR spectroscopy was performed on a Perkin-Elmer Frontier instrument. 
Low–resolution mass spectra (m/z) were obtained in the electrospray ionization (ESI) mode 
on a Waters Micromass ZQ instrument while high–resolution mass spectra (m/z) were 
recorded in the ESI mode on a Micromass LCT instrument. Both spectrometers belong to the 
UBC Mass Spectrometry laboratory. Melting points were measured on on a Mel-Temp 
apparatus and are uncorrected. 
All reagents and solvents were commercial products and used without further purification 
except THF (freshly distilled from Na/benzophenone ketyl under N2) and DCM (freshly 
distilled from CaH2 under N2). 
Flash chromatography was performed on 230-400 mesh silica gel. Analytic TLC was carried 
out on aluminum-backed Merck silica gel 60 plates with fluorescent indicator. Spots were 
visualised with UV light, I2 and alkaline aqueous KMnO4. 
All the reactions were performed in oven-dried flasks equipped with Teflon
TM
 stirbars. All 
flasks were fitted with rubber septa for the introduction of substrates, reagents and solvent 
through a syringe.  
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Dimethyl 2- ((t-butoxycarbonyl)amino)manolate (224) 
 
 
 
To a solution of dimethylmalonate (50 g, 378 mmol, 1.0 equiv) in AcOH (65 mL), stirred 
vigorously at 0 ºC, was dropwise added a solution of NaNO2 (78.33 g, 1135.2 mmol, 3.0 
equiv) in water (500mL). After stirring overnight at RT, the organic layer was separated from 
the aqueous phase, washed with brine (40 mL), concentrated under vacuum and dried over 
sodium sulfate to afford oxime 222 as a white solid (60 g, 373, 9.0 mmol, 99 %).  
Compound 222 (3.0 g, 18.6 mmol, 1.0 equiv) was dissolved in EtOH (40 mL) under argon 
atmosphere, then Pd/C 10 % (0.1 equiv) was added. The solution was stirred overnight at RT 
observing complete reduction of the starting material: to the same flask, was then added 
Boc2O (6.01 g, 27.9 mmol, 1.5 equiv) and stirring proceeded for other 3 hours at RT. The 
solution was filtered through a pad of celite and concentrated under vacuum to give a mixture 
which was purified by flash column chromatography (EtOAc/Hex 10%) to furnish 224 as a 
colorless oil (4.27 g, 17.27 mmol, 79 %). 
 
1
H NMR (CDCl3): δ 5.56 (d, J = 7.5, 1H), 5.01 (d, J = 7.5, 1H), 3.82 (s, 6H), 1.46 (s, 9H) 
13
C NMR (CDCl3): δ 167.04, 154.71, 80.74, 57.17, 53.30, 28.17 
IR: v 3380, 2973, 1746, 1710 cm
-1
 
MS: 246 [M-H
+
] 
HRMS: calcd for C10H18NO6H
+
: 248.1134; found: 248.1132 
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1
H NMR and 
13
C NMR of compound 224. 
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Dimethyl 2- ((t-butoxycarbonyl)amino)-2-((phenylthio)methyl)malonate (225). 
 
 
 
Compound 224 (0.75 g, 3.03, 1.0 equiv) was dissolved in dry DMF (6 mL) under argon 
atmosphere, cooled at 0 ºC and then a 60% dispersion of NaH in mineral oil (0.14 g, 6.06 
mmol, 2.0 equiv) was added. The solution was stirred for 30 min, before adding 
chloromethylphenylsulfane (0.72 g, 4.54 mmol, 1.5 equiv) and a spatula of TBAB. The 
resulting mixture was stirred overnight at RT, then quenched with a 50 % solution 
AcOH/H2O (8 mL). The organic phase was extracted with EtOAC (3 x 10 mL), washed with 
water (5 x 8 mL), dried over sodium sulfate and concentrated in vacuo to yield a crude 
residue which was purified by flash column chromatography (EtOAc/Hex 10 %) to give 225 
as a white solid (0.405 g, 1.09 mmol, 35 %). 
 
Mp: 62-64 ºC 
1
H NMR (CDCl3): δ 7.38 (d, J = 7.9, 2H), 7.28-7.13 (m, 3H), 6.01 (s, 1H), 3.87 (s, 2H), 3.62 
(s, 6H), 1.33 (s, 9H) 
13
C NMR (CDCl3): δ 167.27, 153.81, 134.99, 131.27, 128.90, 126.91, 80.43, 67.14, 53.35, 
38.20, 28.06  
IR: v 3400, 2980, 1752, 1705, 1584 cm
-1
 
MS: 392 [M+Na
+
] 
HRMS: calcd for C17H23NO6SNa
+
: 392.1144; found: 392.1144 
Anal. calcd for C17H23NO6S: N, 3.79; C, 55.27; H, 6. 28. Found: N, 3.87; C, 55.38; H, 6.33   
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1
H NMR and 
13
C NMR of compound 225. 
 
 134 
 
2- ((t-butoxycarbonyl)amino)-3-methoxy-3-oxo-2-((phenylthio)methyl)propanoic acid 
(220).  
 
 
Compound 224 (0, 327 g, 0.88 mmol, 1.0 equiv) was dissolved at RT in a mixture 
MeOH/H2O (2:1 mL) then LiOH·H2O (0.037 g, 0.88 mmol, 1.0 equiv) was added and the 
solution stirred for 3 hours. The organic phase was discarded while the aqueous layer was 
acidified with 1N HCl (1.5 mL). The new organic phase was extracted with EtOAC (3 x 5 
mL), washed with brine and concentrated under vacuum to afford 220 (0, 15 g, 0.42 mmol, 
47 %). 
 
1
H NMR (CDCl3): δ 7.41 (d, J = 7.2, 2H), 7.26-7.12 (m, 3H), 6.08 (s, 1H), 3.87 (s, 2H), 3.62 
(s, 3H), 1.34 (s, 9H) 
13
C NMR (CDCl3): δ 171.11, 168.00, 154.38, 135.24, 131.38, 131.10, 129.06, 128.90, 
126.76, 80.78, 67.51, 53.39, 38.01, 28.23  
IR: 2978, 1724, 1715, 1650 
MS: 378 [M+Na
+
] 
HRMS: calcd for C16H22NO6SH
+
: 356.1168; found: 356.1168  
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1
H NMR and 
13
C of compound 224. 
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Methyl 2-((1S)-1-amino-2-hydroxyethyl)oxazole-4-carboxylate (155) 
 
Commercial L-serine methyl ester hydrochloride (2.27 g, 14.6 mmol, 1.0 equiv) was 
dissolved in dry DCM (15mL) at RT and under argon atmosphere and triethylamine (4.07 
mL, 29.2 mmol, 2.0 equiv) was added. The resulting solution was stirred for 10 min at RT 
before adding N-Boc-O-TBS L-serine (4.66 g, 14.6 mmol, 1.0 equiv). To this solution, HOBt 
(2.15 g, 15.91 mmol, 1.09 equiv) and EDCI (2.94 g, 15.33 mmol, 1.05 equiv) were added in 
portions, then stirring proceeded overnight at RT. 
Saturated aqueous Na2CO3 (20 mL) was poured into the reaction mixture which was then 
extracted with DCM (3 x 15 mL). The combined organic layers were washed with brine (20 
mL), dried over sodium sulfate and concentrated under vacuum to yield a crude residue 
which was purified by flash column chromatography (EtOAc/Hex 30 %)  to give the 
corresponding dipeptide L-serine N-(t-butoxycarbonyl)-O-(t-butyldimethylsilyl)-L-seryl 
methyl ester (4.93 g, 11.72 mmol, 80 %), a colorless oil which solidified on standing. As seen 
below, the latter was fully carachterized. 
Mp: 51-53 ºC 
1
H NMR (CDCl3): δ 7.36 (d, J = 7.2 Hz, 1H) 5.4 (d, J = 7.2 Hz, 1H), 4.65 (app. tripl, J = 3.0 
Hz, 1H), 4.18 (br s, 1H), 4.02 (dd, J = 9.9, 3.9 Hz, 1H), 3.94 (s, 2H), 3.78 (s, 3H), 3.77-3.68 
(m, 2H), 1.46 (s, 9H), 0.88 (s, 9H), 0.08 (s, 6H) 
13
C NMR (CDCl3): δ 170.86, 170.54, 155. 68, 80.32, 63.29, 62.88, 55.89, 54.89, 52.61, 
28.23, 25.74, 18.17, -5.60 ppm 
IR: v 3325, 2931, 1740, 1689, 1646 
MS: 421 [M+H
+
] 
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HRMS: calcd for C18H37N2O7SiH
+
: 421.2370; found: 421.2373  
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A solution of the emerging dipeptide (4.55 g, 10.82 mmol, 1.0 equiv) in dry DCM (20 mL) 
and under argon atmosphere was cooled at -15 ºC before adding Deoxo-Fluor (4.4 mL, 11.9 
mmol, 1.1 equiv, 50% in toluene). The solution was stirred at the same temperature for 30 
min then quenched with saturated aqueous Na2CO3 (20 mL) and allowed to slowly warm up 
to RT. 
The resulting mixture was extracted with DCM (3 x 20 mL) and the combined organic layers 
were washed with brine (30 mL), dried over sodium sulfate and concentrated in vacuo to 
yield the corresponding crude oxazoline which was used without further purification in the 
next step. 
The crude oxazoline (2.66 g, 6.6 mmol, 1.0 equiv) was dissolved in anhydrous DCM (10 mL) 
under argon at 0 ºC, then DBU (1.57 mL, 10.56 mmol, 1.6 equiv) and BrCCl3 (1.9 mL, 9.9 
mmol, 1.5 equiv) were added. After the addition, the cooling bath was removed and the 
solution stirred overnight at RT. 
Saturated aqueous of NH4Cl (15 mL) was poured into the solution, which was then extracted 
with DCM (3 x 10 mL). The combined organic layers were washed with brine (15 mL), dried 
over Na2SO4 and concentrated to dryness under reduced pressure to yield a crude residue 
which was purified by flash column chromatography (EtOAc/Hex 30%). Methyl 2-((1S)-1-(t-
butoxycarbonyl)amino)-2-((t-butyldimethylsilyl)hydroxyethyl)oxazole-4-carboxylate resulted 
tobe a colorless oil (1.537 g, 3.83 mmol, 35.4 % over 2 steps) and  was fully characterized. 
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1
H NMR (CDCl3): δ 8.18 (s, 1H), 5.51 (d, J = 8.1 Hz, 1H), 5.0 (tripl, J = 4.2 Hz, 1H), 4.04 
(dd, J = 10.1, 4.2, Hz, 1H), 3.93 (d, J = 4.2 Hz, 1H), 3.90 (s, 3H), 1.44 (s, 9H), 0.79 (s, 9H), -
0.03 (s, 3 H), -0.06 (s, 3H) 
13
C NMR (CDCl3): δ 163.86, 161.48, 155.09, 144.00, 133.32, 80.16, 64.43, 52.15, 51.14, 
28.24, 25.88, 18.05, -5.65, -5.68 ppm 
IR: v 2931, 1730, 1714 
MS: 423 [M+Na
+
] 
HRMS: calcd for C18H33N2O6SiH
+
: 401.2108; found: 401.2108 
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The resulting oxazole (1.3 g, 3.24 mmol, 1.0 equiv) was dissolved in anhydrous THF (7 mL) 
at RT under argon atmosphere before adding TBAF (1.0 M THF solution, 2.0 equiv). After 
stirring at RT for 1.5 h, the reaction mixture was quenched with water (15 mL) and extracted 
with DCM (3 x 10 mL). The combined organic layers were washed with brine (15 mL), dried 
over Na2SO4 and concentrated in vacuo to give the known alcohol 228 as light yellow oil 
(0.733 g, 2.56 mmol, 79 %). 
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In accord with literature here we reported 
1
H NMR. 
1
H NMR (CDCl3): δ 8.2 (s, 1H), 5.75 (d, J = 7.9 Hz, 1H), 5.02 (d, J = 3.7 Hz, 1H), 3.96 (dd, J
 
= 11.4, 4.0, 1H), 3.89 (s, 3H), 1.43 (s, 9H). 
 
 
The latter was dissolved in HCl / dioxane (4.0 M solution, 5 mL) and the resulting mixture 
was stirred at RT for 3 hours. The solvent was then evaporated under high vacuum to yield 
the known 155 as a white solid.  
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Methyl 2-((tert-butoxycarbonyl)carbamoyl)oxazole-4-carboxylate 232 
 
 
 
Compound 228 (0.37 g, 1.29 mmol, 1.0 equiv) was dissolved in a 1:1 mixture CH3CN / H2O 
(2 mL/2 mL) then BAIB (1.25 g, 3.87 mmol, 3.0 equiv) and cat. TEMPO (10 %) were added. 
The resulting solution was stirred overnight at RT then quenched with saturated aqueous 
Na2SO3 (5 mL) and extracted with EtOAC (3 x 5 mL). The combined organic layers were 
washed with brine (5 mL) and concentrated under vacuum to afford a mixture which was 
purified through flash chromatography (EtOAc/ Hex 50 %) to release 232 as a white solid 
(0.16 g, 0. 60 mmol, 46 %).  
As said in Scheme 58, treating 228 with PCC or DMP also resulted in the formation of 232. 
The latter was partially characterized through 
1
H and 
13
C NMR as well as low resolution 
mass spec. 
1
H NMR (CDCl3): δ 8.98 (s, 1H), 8.41 (s, 1H), 3.98 (s, 3H), 1.54 (s, 9H)  
13
C NMR (CDCl3): δ 160.35, 154. 02, 151.35, 148.12, 147.06, 133.94, 83.78, 52.75, 27.89 
MS: 171 [M-Boc] 
 
 143 
 
 
 
1
H NMR and 
13
C of compound 232. 
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2-((t-butoxycarbonyl)amino)-3,3-diethoxypropanoic acid (238). 
 
To a solution of 234 (3.33 mL, 30.05 mmol, 1.0 equiv) in anhydrous DCM (50 mL) held at -
10 °C under argon atmosphere was slowly added by siringe a 1.0 M  DCM solution of TiCl4 
(33 mmol, 1.1 equiv). The resulting mixture was stirred for 10 min, then N, N-
diisopropilethylamine (5.76 mL, 33 mmol, 1.1 equiv) was added dropwise. Stirring 
proceeded for 40 min at the same temperature before adding triethyl orthoformate (12.5 mL, 
75 mmol, 2.5 equiv). The emerging solution was stirred for other 2.5 h, warmed to 0 ºC and 
quenched with saturated aqueous NaHCO3 (20 mL) until gas evolution ceased. 
The layers were separated and the organic washed with H20 (1 x 10 mL), brine (1 x 10 mL), 
dried over Na2SO4. Concentration to dryness under reduced pressure gave alkylated 
derivative 235 (6.445 g, 27.42 mmol, 91 %) as a reddish oil.  
Compound 235 (2 g, 8.51 mmol, 1.0 equiv) was dissolved in MeOH (15 mL) and 
hydrogenated overnight at atmospheric pressure over Pd/C. The solution was filtrated through 
a pad of celite and concentrated under vacuum to afford compound 236 (1.469 g. 7.15 mmol, 
84 %) as a light yellow oil. 
Amine 236 (1.4 g, 6.92 mmol. 1.0 equiv) was dissolved at RT in dioxane (10 mL).  Boc2O 
(2.26 g, 10.38 mmol, 1.5 equiv) and saturated aqueous NaHCO3 (5 mL) were then added. 
After stirring at the same temperature for 7 h, the reaction mixture was diluted with distilled 
H20 (5 mL) and extracted with EtOAc (3 x 8 mL). The combined organic layers were washed 
with brine (1 x 10 mL) and all volatiles removed in vacuo. The crude was then purified by 
flash column chromatography (silica gel, EtOAc/Hex 10%) furnishing 237 as transparent oil 
(1.2 g, 3.97 mmol, 60 %).  
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Compound 237 (1.2 g, 3.97 mmol, 1.0 equiv) was dissolved at RT in a mixture 2:1 
MeOH/H20 (4mL/2mL) and LiOH·H20 (0.33 g, 7.87 mmol, 2.0 equiv) was added; the 
resulting solution was stirred overnight at RT then the organic phase was discarded while the 
aqueous phase acidified to pH = 3 with 1N HCl (10 mL). The aqueous layer was then 
extracted with EtOAc (2 x 10 mL), and the combined organic extracts were washed with 
brine (10 mL), dried over Na2SO4 and concentrated in vacuo to afford acid 238 as transparent 
oil (1.08 g, 3.88 mmol, 98 %). 
 
1
H NMR (CDCl3): δ 5.35 (d, J = 7.8 Hz, 1H), 4.82 (br s, 1H), 4.51 (d, J = 7.8 Hz, 1H), 3.82-
3.58 (m, 4H), 1.45 (s, 9H), 1.23 (dt, J
 
= 6.9, 3 Hz, 6H) 
13
C NMR (CDCl3): δ 173.46, 155.94, 101.03, 80.26, 64.25, 64.06, 56.03, 28.22, 15.00, 14.86  
IR: v 3449, 2979, 1699 (broad) 
MS: 300 [M+Na
+
] 
HRMS: calcd for C12H23NO6
+
: 300.1423; found: 300.1418 
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1
H NMR and 
13
C of compound 238. 
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(Rac) Methyl 2-(2-((t-butoxycarbonyl)amino)-3,3-diethoxypropanamido)-3- 
hydroxypropanoate (239) 
 
L-serine methyl ester hydrochloride (0.982 g, 3.54 mmol, 1.0 equiv) was dissolved at RT 
under argon atmpshpere in anhydrous DCM (8 mL), Et3N (0.98 mL, 7.08 mmol, 2.0 equiv) 
was added and the solution was stirred for 10 min at RT.  Acid 238 (0.55 g, 3.54 mmol, 1.0 
equiv), HOBt (0.52 g, 3.86 mmol, 1.09 equiv) and DCC (0.76 g, 3.72 mmol, 1.05 equiv) were 
added and the mixture was stirred overnight at the same temperature.  The mixture was 
cooled to 0 ºC before being filtered through a sintered funnel. The filtrate was concentrated to 
70 % of its volume, dissolved in EtOAc (8 mL) and filtrate again at low temperature. 
The filtrate was washed with brine (20 mL), dried over Na2SO4 and concentrated under 
vacuum to yield a crude residue which was purified by flash column chromatography 
(EtOAc/Hex 50 %) ) to give dipeptide 239 (0.86 g, 2.27 mmol, 64 %) as a colorless oil. 
1
H NMR (CDCl3):  δ 7.44 (br s, 1H), 5.52 (app dd, J = 61.6, 5.4 Hz, 1H), 4.78 (br s, 1H), 
4.67-4.57 (m, 1H), 4.33 (bs, 1H), 4.16-4.07 (m, 1H), 3.98-3.92 (m, 1H), 3.86-3.52 (m, 4H), 
3.80 (s, 3H), 1.46 (s, 9H), 1.32-1.16 (m, 6H) 
13
C NMR (CDCl3): δ 170.52, 170.38, 169.28, 167.86, 155.89, 102.52, 101.67, 80.25, 65.85, 
64.63, 63.88, 62.91, 61.99, 57.20, 55.24, 52.67, 28.30, 15.11 ppm 
IR: v 3351, 2977, 1746, 1717, 1668. 
MS: 401 [M+Na
+
] 
HRMS: Calcd for C16H30N2O8Na
+
: 401.1900; found: 401.1896. 
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1
H NMR and 
13
C of compound 239. 
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2-(1-((t-butoxycarbonyl)amino)-2,2-diethoxyethyl)oxazole-4-carboxylic acid 233.  
 
To a stirred solution of dipeptide 239 (1.0 g, 2.64 mmol, 1.0 equiv) in dry DCM (5 mL) under 
argon at -15 ºC, was added a 50% toluene solution of Deoxo-Fluor (1.26 mL, 2.904 mmol, 
1.1 equiv). The solution was stirred at the same temperature and monitored by TLC. After 1h 
the reaction mixture worked-up by the addition of saturated aqueous Na2CO3 (5 mL) and 
allowed to slowly warm to RT. 
The mixture was extracted with DCM (3 x 5 mL), washed with brine (10 mL), dried over 
Na2SO4 and concentrated in vacuo to yield crude oxazoline 240 which was used without 
further purification in the next step. 
Oxazoline 240 (0.7 g, 1.94, 1.0 equiv) was dissolved in DCM (4 mL) under argon at 0 ºC, 
then DBU (0.58 mL, 3.88 mmol, 2.0 equiv) and BrCCl3 (0.37 mL, 3.88 mmol, 2.0 equiv) 
were added. After the addition the cooling bath was removed and the solution stirred 
overnight at RT. 
Saturated aqueous NH4Cl (4 mL) was then poured into the solution and after stirring for 10 
min the latter was extracted with DCM (3 x 5 mL), washed with brine (10 mL), dried over 
Na2SO4 and concentrated in vacuo to yield a crude residue which was purified by flash 
column chromatography (EtOAc/Hex 30 %) to give oxazole 241 (0.45 g, 1.25 mmol, 47 % 
over 2 steps) as colorless oil. Compound 241 (0. 45 g, 1.25 mmol, 1.0 equiv) was dissolved in 
a mixture 2:1 MeOH/H20 (4mL/2mL) and LiOH·H20 (0.1 g, 2.5 mmol, 2.0 equiv) was added; 
the solution was stirred overnight at RT. 
The organic phase was discarded while the aqueous phase acidified to pH = 3 with 1N HCl (3 
mL); the aqueous phase was extracted with EtOAc  (3 x 5 mL), washed with brine (10 mL) 
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and concentrated under vacuum to afford acid 233 as a white solid (0. 32 g, 0.92  mmol, 73 
%). 
 
Mp: 131-133 ºC 
1
H NMR (CDCl3): δ 8.28 (s, 1H) 5.98 (d, J = 8.73, 1H) 5.22-5.13 (m, 1H), 4.81 (d, J = 4.86, 
1 H) 3.79-3.47 (m, 4H), 1.44 (s, 9H), 1.15 (q, J = 6.0, 6H). 
13
C NMR (CDCl3): δ 163.77, 163.63, 55.56, 144.80, 133.29, 101.75, 80.24, 64.06, 62.98, 
51.59, 28.40, 14.94  
MS: 367 [M+Na
+
] 
IR: v 3362.06, 2981.13, 2931.63, 1693.10, 1521.67 
HRMS: calcd for C15H24N2O7Na
+
: 367. 1481, found: 367. 1484 
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1
H NMR and 
13
C of compound 233. 
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(Rac) Methyl 2-(1-(2-(1-((t-butoxycarbonyl)amino)-2,2-diethoxyethyl) 
oxazole-4-carboxamido)-2-hydroxyethyl)oxazole-4-carboxylate (242) 
 
Amine 155 (0.11g, 0.6 mmol, 1.0 equiv) was dissolved in anhydrous DCM (2 mL) under 
argon atmosphere, then Et3N (0.08 mL, 0.6 mmol, 1.0 equiv) was added and the solution 
stirred for 10 min; to this solution acid 233 (0.21 g, 0.6 mmol, 1.0 equiv) was first added, 
followed by HOBt (0.09 g, 0.65 mmol, 1.09 equiv) and EDCI (0.12 g, 0.63 mmol, 1.05 
equiv); the resulting mixture was stirred overnight at RT. 
The reaction was quenched with saturated aqueous Na2CO3 (2 mL) and extracted with DCM 
(3 x 2 mL).  The combined organic layers were washed with brine (5 mL), dried over Na2SO4 
and concentrated under vacuum to yield a crude residue which was purified by flash column 
chromatography (EtOAc/Hex 50 %) to give compound 242 (0.3 g, 0.58 mmol, 96 %) as a 
light yellow oil. 
1
H NMR (CDCl3): δ 8.22 (s, 1H), 8.18 (s, 1H), 7.90-7.75 (m, 1H), 5.60-5.39 (m, 2H,), 5.05 
(br s, 1H), 4.74-4.70 (m, 1H), 4.11-3.99 (m, 1H), 3.90 (s, 1H), 3.79-3.43 (m, 4H) 1.44 (s, 9H) 
1.22-1.10 (m, 6H). 
13
C NMR (CDCl3): δ 162.75, 161.66, 161.32, 160.56, 155.39, 144.47, 141.92, 135.43, 
133.14, 101.53, 80.44, 63.97, 63.91, 63.32, 63.09, 52.22, 48.91, 48.81, 28.91, 15.02  
IR: v 3344.08, 2979, 1725, 1720, 1710 
MS: 535 [M+Na
+
] 
HRMS: calcd for C36H27N2O3Na
+
: 535.2022; found: 535.2021 
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1
H NMR and 
13
C of compound 242. 
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Methyl 2''-(1-((t-butoxycarbonyl)amino)-2,2-diethoxyethyl)-2-4’,2'-4''-teroxazole 
-4-carboxylate (208). 
 
To a stirred solution of 242 (0.3 g, 0.58 mmol, 1.0 equiv) in dry DCM (1 mL) under argon 
atmosphere at -15 ºC, was added Deoxo-Fluor (0.28 mL, 1.1 equiv, 50 % in toluene). The 
solution was stirred for 2 h at the same temperature, then worke-uo vy the addition of 
saturated aqueous solution Na2CO3 (1.5 mL) and allowed to slowly warm to RT. 
The reaction mixture was extracted with DCM (3 x 1 mL), washed with brine (3 mL), dried 
over Na2SO4 and concentrated in vacuo to yield oxazoline 243 which was used without 
further purification in the next step. 
Crude oxazoline 243 (0.26 g, 0.52 mmol, 1.0 equiv) was dissolved in DCM (2 mL) under 
argon at 0 ºC, then DBU (0. 15 mL, 1.04 mmol 2.0 equiv) and BrCCl3 (0.1 mL, 1.04 mmol, 
2.0 equiv 2.0 equiv) were added. After the addition, the cooling bath was removed and the 
solution was stirred overnight at RT. 
Saturated aqueous NH4Cl (2 mL) was poured into the solution and after stirring for 10 min 
the latter was extracted with DCM (3 x 2 mL). The combined organic layers were washed 
with brine (5 mL), dried over Na2SO4 and concentrated in vacuo to yield a crude residue 
which was purified by flash column chromatography (EtOAc/Hex 50 %) to give  tris-oxazole 
208 (0.15 g, 0.3 mmol, 57 %) as a dark white solid. 
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Mp: 218-220 Cº 
1
H NMR (CDCl3): δ 8.41 (s, 1H), 8.31 (s, 2H), 5.23 (d, J = 8.31, 1H), 5.16-5.09 (m, 1H), 4.80 
(d, J = 4.77, 1H), 3.93 (s, 3H), 3.76-3.48 (m, 4H), 1.42 (s, 9H), 1.14 (q, J = 6.0 Hz, 6H). 
13
C NMR (CDCl3): δ 163.23, 161.27, 156.12, 155.39, 143.87, 139.63, 139.29, 134.34, 
130.76, 129.80, 101.81, 80.31, 64.11, 63.42, 52.32, 51.68, 28.22, 15.03 
IR: v 3355, 2980, 1721, 1696 
MS: 515 [M+Na
+
] 
HRMS: calcd for C22H28N4O9Na
+
: 515.1754; found: 515. 1760 
Anal calcd for C 53.65, H 5.73, N 11.38; found C 53.11 H 5.84, N 10.85 
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1
H and 
13
C NMR of compound 233. 
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L-serine N-(t-butoxycarbonyl)-O-(t-butyldimethylsilyl)-L-threonyl methyl ester (211) 
 
Commercial N-Boc L-threonine (1.0 g, 4.56 mmol, 1.0 equiv) was dissolved in anhydrous 
DMF (5 mL) at RT under argon atmosphere and imidazole (0.62 g, 9.12 mmol, 2.0 equiv) 
was added. The solution was stirred for 10 min before adding TBSCl (0.72g, 4.78 mmol, 1.05 
equiv). Stirring proceeded overnight at RT. 
The mixture was diluted with EtOAc (10 mL), washed with water (5 x 3 mL), brine (10 mL), 
dried over Na2SO4 and concentrated in vacuo to afford a residue which was purified via flash 
column chromatography (silica gel, EtOAc/ Hex 30%) to afford 210 as a white solid (0.91 g, 
2.73 mmol, 60 %). 
Acid 210 (0.86 g, 2.6 mmol, 1.0 equiv) was dissolved in dry DCM (5 mL) under argon 
atmpshpere, then Et3N (0.72 mL, 5.2 mmol, 2.0 equiv) was added and the solution stirred for 
10 min at RT. To this solution, L-serine methyl ester hydrochloride (0.4 g, 2.6 mmol, 1.0 
equiv) was added followed by the addition of HOBt (0.38 g, 2.83 mmol, 1.09 equiv) and 
EDCI (0.52 g, 2.73 mmol, 1.05 equiv). The resulting mixture was stirred overnight at RT. 
The reaction was worked-up by the addition of saturated aqueous Na2CO3 (4 mL) and 
extracted with DCM (3 x 5 mL).  The combined organic layers were washed with brine (10 
mL), dried over Na2SO4 and concentrated under vacuum to yield a crude residue which was 
purified by flash column chromatography (silica gel, EtOAc/Hex 30% ) to give dipeptide 211 
(0.83 g, 1.9 mmol, 73 %) as a light yellow oil. 
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1
H NMR (CDCl3): δ 7.53 (d, J = 6.3 Hz, 1H), 5.43 (d, J = 6.3 Hz, 1H), 4.66 (quint,  J = 3.6 
Hz, 1H), 4.41-4.31 (m, 1H), 4.20-4.09 (m, 1H), 3.98 (dd, J = 11.2, 3.7 Hz, 1H), 3.88 (dd, J = 
11.2, 3.4, 1H), 3.78 (s, 3H), 1.46 (s, 9H), 1.15 (d, J = 6.3 Hz, 1H), 0.89 (s, 9H), 0.11 (s, 6H) 
13
C NMR (CDCl3): 170.83, 170.77, 155.99, 80.23, 68.65, 63.35, 59.61, 54.94, 52.78, 34.06, 
28.48, 25.91, 18.98, -4.48, -4.90 
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1
H and 
13
C NMR of compound 211. 
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Methyl 2-((1S, 2R)-1-(t-butoxycarbonyl)amino-2-(t-butyldimethylsilyl)hydroxypropyl) 
oxazole-4-carboxylate (213) 
 
To a solution of dipeptide 211 (0.852 g, 1.96 mmol, 1.0 equiv) in dry DCM (4 mL) under 
argon atmosphere at -15 ºC, was added Deoxo-Fluor (0.78 mL, 1.1 equiv, 50 % in toluene). 
The solution was stirred for 30 min at the same temperature, then quenched with saturated 
aqueous Na2CO3 (4 mL) and allowed to slowly warm to RT. 
The reaction mixture was extracted with DCM (3 x 5 mL), washed with brine (10 mL), dried 
over Na2SO4 and concentrated in vacuo to yield oxazoline 212 (0.52 g, 1.26 mmol, 64 %), 
which was used without further purification in the next step. 
Crude oxazoline 212 (0.52 g, 1.26 mmol, 1.0 equiv) was dissolved in dry DCM (3 mL) under 
argon atmosphere. Thesolution was cooled to 0 ºC, then DBU (0. 28 mL, 1.89 mmol, 1.5 
equiv) and BrCCl3 (0.19 mL, 2.016 mmol, 1.6 equiv) were added. After the addition the 
cooling bath was removed and the solution stirred overnight at RT. 
Saturated aqueous NH4Cl (3 mL) was poured into the solution and after stirring for 10 min it 
was extracted with DCM (3 x 3 mL), washed with brine (5 mL), dried over Na2CO3 and 
concentrated in vacuo to yield a crude residue which was purified by flash column 
chromatography (silica gel, EtOAc/Hex 10 %) to give oxazole 213 (0.35 g, 0.84 mmol, 67 %) 
as a light yellow oil. 
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1
H NMR (CDCl3): δ 8.16 (s, 1H), 5.44 (d, J = 9.6 Hz, 1H), 4.88 (d, J = 9.6 Hz, 1H), 3.93 (s, 
3H), 4.39 (d, J = 6.0 Hz, 1H), 3.9 (s, 3H), 1.46 (s, 9H), 1.23 (d, J = 6.0 Hz, 1H), 0.76 (s, 9H), 
- 0.03 (s, 3H), - 0.23 (s, 3H) ppm 
13
C NMR (CDCl3): 163.23, 161.27, 156.12, 155.39, 143.87, 139.63, 139.29, 134.34, 130.76, 
129.80, 101.81, 80.31, 64.11, 63.42, 52.32, 51.68, 28.22, 15.03 ppm 
IR: 1717.33, 1497. 06, 1321.90 (ring stretch), 1140 (ring breathing) 
MS: 415 [M+H
+
] 
HRMS: calcd for C19H35N2O6SiH
+
: 415.2264, found: 415.2267 
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1
H and 
13
C NMR of compound 213. 
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Methyl 2-((1S, 2R)-1-(t-butoxycarbonyl)amino-2-(t-butyldimethylsilyl)hydroxypropyl) 
oxazole-4-carboxylate hydrochloride (124) 
 
Oxazole 213 (1.66 g, 4.0 mmol, 1.0 equiv) was dissolved in dry THF (10 mL) under argon 
atmosphere. The solution was cooled to 0 ºC before adding a 1.0 M THF solution of TBAF 
(4.4 mmol, 1.1 equiv). After the addition, the cooling bath was removed and the solution was 
stirred overnight at RT. The reaction mixture was quenched with water (10 mL) and extracted 
with EtOAc (3 x 8 mL), washed with brine (15 mL), dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by flash chromatography (EtOAc/Hex 30%) furnishing 
alcohol 214 as a light yellow solid (0.644 g, 2.14 mmol, 53 %).  
Compound 214 (0.25 g, 0. 83 mmol, 1.0 equiv) was dissolved at 0 ºC in 1,4-dioxane (0.4 
mL), then 4M HCl in dioxane (1.2 mL) was added. The solution was stirred for 2 hours at the 
same temperature, concentrated under vacuum to afford amine hydrochloride 124 as light 
yellow oil (0.16 g, 0. 83, 100 %). 
 
1
H NMR (CD3CN): δ 8.43 (s, 1H), 4.5 (d, J = 6.0 Hz, 1H), 4.25 (br s, 1H), 3. 87 (s, 3H), 1.96 
(s, 2H), 1.22 (d, J = 6.0 Hz, 3H) ppm 
13
C NMR (CD3CN): δ 161.81, 159. 85, 145.53, 132.80, 66.60, 54.51, 52.26, 18.91  
MS: 201 [M+H
+
] 
HRMS: Calcd for C8H12N2O4
+
: 201.0875, found: 201. 0874 
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1
H NMR and 
13
C of compound 124. 
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L-threonine N-(t-butoxycarbonyl)-S-(t-butyl)-L-cysteyl methyl ester (216) 
 
 
 
Commercial L-threonine methyl ester hydrochloride (1.83 g, 10.81 mmol, 1.0 equiv) was 
dissolved in anhydrous DCM (20 mL) at RT under argon atmosphere, then Et3N (1.5 mL, 
10.81 mmol, 1.0 equiv) was added and the solution was stirred for 10 min. To this solution, 
was added N-(t-butoxycarbonyl)-S-(t-butyl)-L-cysteine (215, 1.83 g, 10.81 mmol, 1.0 equiv), 
followed by the addition of HOBt (1.59 g, 11.78 mmol, 1.09 equiv) and DCC (2.34 g, 11.35 
mmol, 1.05 equiv). The resulting mixture was stirred overnight at RT. 
The mixture was cooled to 0 ºC before being filtered through a sintered funnel. The filtrate 
was concentrated to 70 % of its volume, dissolved in EtOAc (8 mL) and filtrate again at low 
temperature. 
The filtrate was treated with saturated aqueous Na2CO3 (10 mL), extracted with EtOAc (3 x 
10 mL), washed with brine (20 mL), dried over Na2SO4 and concentrated under vacuum to 
yield a crude residue which was purified by flash column chromatography (EtOAc/Hex 50 
%) to give dipeptide 216 (3.6 g, 9.17 mmol, 85 %) as a colorless thick foam. 
1
H NMR (CDCl3): δ 7.14 (d, J = 8.9, 1H), 4.59 (dd, J = 8.9, 2.7), 4.38-4.28 (m, 2H), 3.76 (s, 
3H), 3.25 (bs, 1H), 3.00 (dd, J = 12.8, 6.4, 1H), 2.87 (dd, J = 12.8, 5.8, 1H), 1.44 (s, 9H), 
1.32 (s, 9H). 
13
C NMR (CDCl3): δ 171.3, 171.0, 155.5, 80.3, 68.0, 57.5, 54.3, 52.5, 42.6, 30.5, 28.2, 19.8  
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Methyl 2-((1S)-1-(t-butoxycarbonyl)amino-2-(t-butylthio)ethyl)-5-methyloxazole-4-
carboxylate (218) 
 
To a solution of dipeptide 216 (0.976 g, 2.5 mmol, 1.0 equiv) in dry DCM (5 mL) under 
argon atmosphere held at -15 ºC, was added Deoxo-Fluor (1.2 mL, 1.1 equiv, 50 % in 
toluene). The solution was stirred for 2.5 hours at the same temperature, then quenched with a 
sat aq solution of Na2CO3 (6 mL) and allowed to slowly warm to RT. 
The reaction mixture was extracted with DCM (3 x 5 mL), washed with brine (8 mL), dried 
over Na2SO4 and concentrated in vacuo to yield crude oxazoline 217 (0.86 g, 2.3 mmol, 92 
%), which was used without further purification in the next step. 
Crude oxazoline 217 (0.86 g, 2.3 mmol, 1.0 equiv) was dissolved in dry DCM (5 mL) under 
argon. The solution was cooled to 0 ºC, then DBU (0.68 mL, 4.6 mmol, 2.0 equiv) and 
BrCCl3 (0.44 mL, 4.6 mmol, 2.0 equiv) were added. The cooling bath was removed and the 
solution stirred for two days at RT. 
Saturated aqueous NH4Cl (5 mL) was then poured into the solution and after stirring for 10 
minit was extracted with DCM (3 x 4 mL), washed with brine (6 mL), dried over Na2SO4 and 
concentrated in vacuo to yield a crude residue which was purified by flash column 
chromatography (silica gel, EtOAc/Hex 30 %) to give oxazole 218 (0.45 g, 1.2 mmol, 52 %) 
as a yellow oil. 
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In accord with literature, here we reported 
1
H NMR of 218. 
1
H NMR (CDCl3) δ 5.46 (br s, 1H), 5.08 (br s, 1H), 3.88 (s, 3H), 3.09-2.96 (m, 2H), 2.59 (s, 
3H), 1.42 (s, 9H), 1.27 (s, 9H) 
 
1
H NMR of 218 
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Methyl 2-((S)-1-(2-((1R)-1-(t-butoxycarbonylamino)-2-t-butylthioethyl)oxazole-4- 
carboxamido)-2-hydroxypropyl)oxazole-4-carboxylate (125) 
 
Oxazole 218 (0.45 g, 1.2 mmol, 1.0 equiv) was dissolved at RT in a mixture 2:1 MeOH/H20 
(4mL/2mL) and LiOH·H2O (0.11 g, 2.76 mmol, 2.3 equiv) was added; the solution was then 
stirred overnight at the same temperature. 
The organic phase was discarded while the aqueous phase acidified to pH = 3 with 1N HCl (3 
mL); the solution was then extracted with EtOAc (3 x 3 mL), washed with brine (5 mL) and 
concentrated under vacuum to afford acid 123 as a light yellow solid (0.33 g, 0.92  mmol, 77 
%). 
Amine 124 (0.16 g, 0.83 mmol, 1.0 equiv) was dissolved in anhydrous DCM (2 mL) under 
argon atmosphere at RT, then Et3N (0.23 mL, 2.0 equiv) was added and the solution stirred 
for 10 min; to this solution acid 123 (0.3 g, 0.83 mmol, 1.0 equiv) was first added, followed 
by HOBt (0.12 g, 0.9 mmol, 1.09 equiv) and EDCI (0.16 g, 0.87 mmol, 1.05 equiv); the 
resulting mixture was stirred for two days at RT. 
The reaction was worked-up by the addition of saturated aqueous Na2CO3 (2 mL) and 
extracted with DCM (3 x 2 mL). The combined organic layers were washed with brine (5 
mL), dried over Na2SO4 and concentrated to dryness. The crude residue was purified by flash 
column chromatography (silica gel, EtOAc/Hex 30 %) to yield amide 125 (0.126 g, 0.23 
mmol, 28 %) as a light yellow oil.  
The reaction showed to be slow: indeed, together with 125 was also recovered a 50 % of both 
starting materials. 
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In accord with literature, here we reported 
1
H NMR of 125. 
1
H NMR (CDCl3): δ 8.20 (s, 1H), 7.71 (d, J = 9.0 Hz, 1H), 5.44 (d, J = 9.0 Hz, 1H), 5.31 (dd, 
J = 9.0, 2.7 Hz, 1H), 5.05 (br s, 1H), 4.61-4.52 (m, 1H), 3.90 (s, 3H), 3.10-2.98 (m, 2H), 2.62 
(s, 3H), 1.45 (s, 9H), 1.30 (s, 9H), 1.28 (d, J = 1.2 Hz, 3H) 
 
1
H NMR of compound 125 
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Methyl 2’’-((1R)-1-(t-butoxycarbonylamino)-2-t-butylthioethyl)-(5’-5’’-dimethyl)- 
2,4’-2’,4’’-teroxazole-4-carboxylate (119) 
 
To a stirred solution of 125 (0.126 g, 0.23 mmol, 1.0 equiv) in dry DCM (0.5 mL) under 
argon atmosphere held at -15 ºC, was added Deoxo-Fluor (0.11 mL, 1.1 equiv, 50 % in 
toluene). The solution was stirred for 2 h at the same temperature, then worked-up by the 
addition of  saturated aqueous Na2CO3 (1.5 mL) and allowed to slowly warm to RT. 
The reaction mixture was extracted with DCM (3 x 1 mL), washed with brine (2 mL), dried 
over Na2SO4 and concentrated in vacuo to yield the corresponding oxazoline (0.1 g, 0.19 
mmol, 82 %) which was used without further purification in the next step. The crude 
oxazoline (0.1 g, 0.19 mmol, 1.0 equiv) was dissolved in DCM (0.4 mL) under argon at 0 ºC, 
then DBU (0. 05 mL, 0.38 mmol 2.0 equiv) and BrCCl3 (0.04 mL, 0.38 mmol, 2.0 equiv) 
were added. After the addition, the cooling bath was removed and the solution stirred for two 
days at RT. 
Saturated aqueous NH4Cl (1 mL) was then poured into the solution and after stirring for 10 
min the latter was extracted with DCM (3 x 1 mL). The combined organic layers were 
washed with brine (2 mL), dried over Na2SO4 and concentrated to dryness. The crude residue 
was purified by flash column chromatography (EtOAc/Hex 50 %) to afford tris-oxazole 119 
(0.04 g, 0.07 mmol, 37 %) as a yellow oil. 
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In accord with literature, here we reported 
1
H NMR of 119. 
1
H NMR (CDCl3) δ 8.29 (s, 1H), 5.52 (brs, 1H), 5.12 (brs, 1H), 3.94 (s, 3H), 3.12-2.98 (m, 
2H), 2.79 (s, 3H), 2.71 (s, 3H), 1.45 (s, 9H), 1.30 (s, 9H) 
 
 
1
H NMR of compound 119 
 
 
 
